ArrayFilename,Sample_title,Sample_geo_accession,Sample_status,Sample_submission_date,Sample_last_update_date,Sample_type,Sample_channel_count,Sample_source_name_ch1,Sample_organism_ch1,Sample_characteristics_ch1,cohort,disease_type,treatment,Batch,Race,Sex,Age,Region,SLEDAI,adna_anti-dsdna,antidsdna,Sample_characteristics_ch1.12,Sample_characteristics_ch1.13,Sample_characteristics_ch1.14,Sample_characteristics_ch1.15,Sample_characteristics_ch1.16,Sample_treatment_protocol_ch1,Sample_molecule_ch1,Sample_extract_protocol_ch1,Sample_label_ch1,Sample_label_protocol_ch1,Sample_taxid_ch1,Sample_hyb_protocol,Sample_scan_protocol,Sample_description,Sample_data_processing,Sample_platform_id,Sample_contact_name,Sample_contact_email,Sample_contact_phone,Sample_contact_department,Sample_contact_institute,Sample_contact_address,Sample_contact_city,Sample_contact_state,Sample_contact_zip.postal_code,Sample_contact_country,Sample_supplementary_file,Sample_data_row_count,Sample_relation,series_matrix_table_begin,ID_REF
GSM2353601_A52084400939409101115421438971278.CEL,"SUBJ.0998, SLE, baseline",GSM2353601,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0998,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,39.50958904,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 84,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.843,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.073,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353601/suppl/GSM2353601_A52084400939409101115421438971278.CEL.gz,0,Reanalyzed by: GSM2352610,NA,GSM2353601
GSM2353602_A52084400939496101415421438760416.CEL,"SUBJ.0998, SLE, week16",GSM2353602,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0998,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,39.50958904,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 84,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.843,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.073,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353602/suppl/GSM2353602_A52084400939496101415421438760416.CEL.gz,0,,NA,GSM2353602
GSM2353603_A52084400939411101115421438971401.CEL,"SUBJ.0998, SLE, week52",GSM2353603,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0998,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,39.50958904,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 84,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.843,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.073,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353603/suppl/GSM2353603_A52084400939411101115421438971401.CEL.gz,0,,NA,GSM2353603
GSM2353604_A52084400940082100815421437950488.CEL,"SUBJ.0112, SLE, baseline",GSM2353604,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0112,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.72677596,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 106,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353604/suppl/GSM2353604_A52084400940082100815421437950488.CEL.gz,0,Reanalyzed by: GSM2352013,NA,GSM2353604
GSM2353605_A52084400940082100815421437950452.CEL,"SUBJ.0112, SLE, week16",GSM2353605,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0112,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.72677596,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 106,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353605/suppl/GSM2353605_A52084400940082100815421437950452.CEL.gz,0,,NA,GSM2353605
GSM2353606_A52084400940082100815421437950457.CEL,"SUBJ.0112, SLE, week52",GSM2353606,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0112,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.72677596,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 106,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353606/suppl/GSM2353606_A52084400940082100815421437950457.CEL.gz,0,,NA,GSM2353606
GSM2353607_A52084400940729100515421373263948.CEL,"SUBJ.0984, SLE, baseline",GSM2353607,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0984,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,23.8579235,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 49,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.997,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.096,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353607/suppl/GSM2353607_A52084400940729100515421373263948.CEL.gz,0,Reanalyzed by: GSM2351878,NA,GSM2353607
GSM2353608_A52084400940729100515421373263951.CEL,"SUBJ.0984, SLE, week16",GSM2353608,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0984,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,23.8579235,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 49,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.997,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.096,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353608/suppl/GSM2353608_A52084400940729100515421373263951.CEL.gz,0,,NA,GSM2353608
GSM2353609_A52084400940728100515421373263881.CEL,"SUBJ.0984, SLE, week52",GSM2353609,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0984,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,23.8579235,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 49,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.997,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.096,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353609/suppl/GSM2353609_A52084400940728100515421373263881.CEL.gz,0,,NA,GSM2353609
GSM2353610_A52084400940070100715421373649393.CEL,"SUBJ.0775, SLE, baseline",GSM2353610,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0775,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,24.47123288,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.639,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.064,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353610/suppl/GSM2353610_A52084400940070100715421373649393.CEL.gz,0,Reanalyzed by: GSM2350936,NA,GSM2353610
GSM2353611_A52084400940070100715421373649427.CEL,"SUBJ.0775, SLE, week16",GSM2353611,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0775,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,24.47123288,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.639,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.064,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353611/suppl/GSM2353611_A52084400940070100715421373649427.CEL.gz,0,,NA,GSM2353611
GSM2353612_A52084400940069100715421373649364.CEL,"SUBJ.0775, SLE, week52",GSM2353612,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0775,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,24.47123288,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.639,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.064,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353612/suppl/GSM2353612_A52084400940069100715421373649364.CEL.gz,0,,NA,GSM2353612
GSM2353613_A52084400940082100815421437950444.CEL,"SUBJ.1564, SLE, baseline",GSM2353613,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1564,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,42.3260274,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.73,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.129,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353613/suppl/GSM2353613_A52084400940082100815421437950444.CEL.gz,0,Reanalyzed by: GSM2351363,NA,GSM2353613
GSM2353614_A52084400940080100815421437950324.CEL,"SUBJ.1564, SLE, week16",GSM2353614,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1564,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,42.3260274,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.73,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.129,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353614/suppl/GSM2353614_A52084400940080100815421437950324.CEL.gz,0,,NA,GSM2353614
GSM2353615_A52084400940081100815421437950397.CEL,"SUBJ.1564, SLE, week52",GSM2353615,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1564,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,42.3260274,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.73,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.129,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353615/suppl/GSM2353615_A52084400940081100815421437950397.CEL.gz,0,,NA,GSM2353615
GSM2353616_A52084400940070100715421373649431.CEL,"SUBJ.1486, SLE, week16",GSM2353616,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1486,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,24.90983607,mex_ca_sa,13,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.286,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353616/suppl/GSM2353616_A52084400940070100715421373649431.CEL.gz,0,,NA,GSM2353616
GSM2353617_A52084400939496101415421438760395.CEL,"SUBJ.1486, SLE, week52",GSM2353617,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1486,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,24.90983607,mex_ca_sa,13,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.286,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353617/suppl/GSM2353617_A52084400939496101415421438760395.CEL.gz,0,,NA,GSM2353617
GSM2353618_A52084400940144101215421438273224.CEL,"SUBJ.0453, SLE, baseline",GSM2353618,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0453,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,44.57534247,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.58,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.243,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353618/suppl/GSM2353618_A52084400940144101215421438273224.CEL.gz,0,Reanalyzed by: GSM2351415,NA,GSM2353618
GSM2353619_A52084400940144101215421438273217.CEL,"SUBJ.0453, SLE, week16",GSM2353619,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0453,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,44.57534247,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.58,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.243,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353619/suppl/GSM2353619_A52084400940144101215421438273217.CEL.gz,0,,NA,GSM2353619
GSM2353620_A52084400940103100915421438150746.CEL,"SUBJ.0453, SLE, week52",GSM2353620,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0453,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,44.57534247,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.58,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.243,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353620/suppl/GSM2353620_A52084400940103100915421438150746.CEL.gz,0,,NA,GSM2353620
GSM2353621_A52084400939702101515421439062135.CEL,"SUBJ.1812, SLE, baseline",GSM2353621,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1812,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.51232877,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 16,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.995,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.192,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353621/suppl/GSM2353621_A52084400939702101515421439062135.CEL.gz,0,Reanalyzed by: GSM2351944,NA,GSM2353621
GSM2353622_A52084400939704101515421439062266.CEL,"SUBJ.1812, SLE, week16",GSM2353622,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1812,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.51232877,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 16,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.995,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.192,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353622/suppl/GSM2353622_A52084400939704101515421439062266.CEL.gz,0,,NA,GSM2353622
GSM2353623_A52084400939705101515421439062290.CEL,"SUBJ.1812, SLE, week52",GSM2353623,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1812,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.51232877,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 16,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.995,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.192,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353623/suppl/GSM2353623_A52084400939705101515421439062290.CEL.gz,0,,NA,GSM2353623
GSM2353624_A52084400940141101215421438273056.CEL,"SUBJ.1320, SLE, baseline",GSM2353624,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1320,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,55.47123288,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H,c3_at_baseline (g/l): 1.9,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.399,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353624/suppl/GSM2353624_A52084400940141101215421438273056.CEL.gz,0,Reanalyzed by: GSM2351901,NA,GSM2353624
GSM2353625_A52084400940143101215421438273155.CEL,"SUBJ.1320, SLE, week16",GSM2353625,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1320,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,55.47123288,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H,c3_at_baseline (g/l): 1.9,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.399,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353625/suppl/GSM2353625_A52084400940143101215421438273155.CEL.gz,0,,NA,GSM2353625
GSM2353626_A52084400940143101215421438273146.CEL,"SUBJ.1320, SLE, week52",GSM2353626,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1320,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,55.47123288,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H,c3_at_baseline (g/l): 1.9,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.399,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353626/suppl/GSM2353626_A52084400940143101215421438273146.CEL.gz,0,,NA,GSM2353626
GSM2353627_A52084400940081100815421437950406.CEL,"SUBJ.0382, SLE, baseline",GSM2353627,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0382,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,53.22465753,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.19,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.078,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353627/suppl/GSM2353627_A52084400940081100815421437950406.CEL.gz,0,Reanalyzed by: GSM2351598,NA,GSM2353627
GSM2353628_A52084400940081100815421437950384.CEL,"SUBJ.0382, SLE, week16",GSM2353628,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0382,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,53.22465753,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.19,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.078,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353628/suppl/GSM2353628_A52084400940081100815421437950384.CEL.gz,0,,NA,GSM2353628
GSM2353629_A52084400940081100815421437950421.CEL,"SUBJ.0382, SLE, week52",GSM2353629,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0382,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,53.22465753,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.19,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.078,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353629/suppl/GSM2353629_A52084400940081100815421437950421.CEL.gz,0,,NA,GSM2353629
GSM2353630_A52084400940103100915421438150735.CEL,"SUBJ.1273, SLE, baseline",GSM2353630,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1273,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,30.90136986,us_can,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.19,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353630/suppl/GSM2353630_A52084400940103100915421438150735.CEL.gz,0,Reanalyzed by: GSM2351989,NA,GSM2353630
GSM2353631_A52084400940103100915421438150740.CEL,"SUBJ.1273, SLE, week16",GSM2353631,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1273,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,30.90136986,us_can,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.19,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353631/suppl/GSM2353631_A52084400940103100915421438150740.CEL.gz,0,,NA,GSM2353631
GSM2353632_A52084400940102100915421438150664.CEL,"SUBJ.1273, SLE, week52",GSM2353632,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1273,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,30.90136986,us_can,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.19,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353632/suppl/GSM2353632_A52084400940102100915421438150664.CEL.gz,0,,NA,GSM2353632
GSM2353633_A52084400940728100515421373263856.CEL,"SUBJ.1195, SLE, baseline",GSM2353633,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1195,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,35.09315068,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 77,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.712,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.158,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353633/suppl/GSM2353633_A52084400940728100515421373263856.CEL.gz,0,Reanalyzed by: GSM2351801,NA,GSM2353633
GSM2353634_A52084400940726100515421373263767.CEL,"SUBJ.1195, SLE, week16",GSM2353634,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1195,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,35.09315068,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 77,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.712,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.158,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353634/suppl/GSM2353634_A52084400940726100515421373263767.CEL.gz,0,,NA,GSM2353634
GSM2353635_A52084400940728100515421373263877.CEL,"SUBJ.1195, SLE, week52",GSM2353635,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1195,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,35.09315068,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 77,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.712,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.158,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353635/suppl/GSM2353635_A52084400940728100515421373263877.CEL.gz,0,,NA,GSM2353635
GSM2353636_A52084400939559101515421438861396.CEL,"SUBJ.1540, SLE, week16",GSM2353636,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1540,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,55.76986301,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.826,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353636/suppl/GSM2353636_A52084400939559101515421438861396.CEL.gz,0,,NA,GSM2353636
GSM2353637_A52084400939496101415421438775739.CEL,"SUBJ.1540, SLE, week52",GSM2353637,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1540,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,55.76986301,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.826,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353637/suppl/GSM2353637_A52084400939496101415421438775739.CEL.gz,0,,NA,GSM2353637
GSM2353638_A52084400940080100815421437950329.CEL,"SUBJ.1292, SLE, baseline",GSM2353638,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1292,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,62.03013699,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 46,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.37,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.163,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353638/suppl/GSM2353638_A52084400940080100815421437950329.CEL.gz,0,Reanalyzed by: GSM2352257,NA,GSM2353638
GSM2353639_A52084400940083100815421437950503.CEL,"SUBJ.1292, SLE, week16",GSM2353639,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1292,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,62.03013699,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 46,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.37,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.163,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353639/suppl/GSM2353639_A52084400940083100815421437950503.CEL.gz,0,,NA,GSM2353639
GSM2353640_A52084400940727100515421373263829.CEL,"SUBJ.1292, SLE, week52",GSM2353640,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1292,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,62.03013699,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 46,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.37,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.163,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353640/suppl/GSM2353640_A52084400940727100515421373263829.CEL.gz,0,,NA,GSM2353640
GSM2353641_A52084400940080100815421437950344.CEL,"SUBJ.0813, SLE, baseline",GSM2353641,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0813,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,44.19178082,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 13,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.834,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.18,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353641/suppl/GSM2353641_A52084400940080100815421437950344.CEL.gz,0,Reanalyzed by: GSM2351171,NA,GSM2353641
GSM2353642_A52084400940080100815421437950336.CEL,"SUBJ.0813, SLE, week16",GSM2353642,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0813,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,44.19178082,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 13,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.834,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.18,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353642/suppl/GSM2353642_A52084400940080100815421437950336.CEL.gz,0,,NA,GSM2353642
GSM2353643_A52084400940083100815421437950505.CEL,"SUBJ.0813, SLE, week52",GSM2353643,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0813,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,44.19178082,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 13,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.834,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.18,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353643/suppl/GSM2353643_A52084400940083100815421437950505.CEL.gz,0,,NA,GSM2353643
GSM2353644_A52084400939411101115421438971402.CEL,"SUBJ.1479, SLE, baseline",GSM2353644,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1479,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,36.70491803,mex_ca_sa,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 33,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.642,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.117,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353644/suppl/GSM2353644_A52084400939411101115421438971402.CEL.gz,0,Reanalyzed by: GSM2352272,NA,GSM2353644
GSM2353645_A52084400939495101415421438760325.CEL,"SUBJ.1479, SLE, week16",GSM2353645,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1479,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,36.70491803,mex_ca_sa,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 33,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.642,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.117,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353645/suppl/GSM2353645_A52084400939495101415421438760325.CEL.gz,0,,NA,GSM2353645
GSM2353646_A52084400940143101215421438273154.CEL,"SUBJ.1479, SLE, week52",GSM2353646,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1479,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,36.70491803,mex_ca_sa,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 33,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.642,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.117,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353646/suppl/GSM2353646_A52084400940143101215421438273154.CEL.gz,0,,NA,GSM2353646
GSM2353647_A52084400940118100915421438150812.CEL,"SUBJ.1228, SLE, baseline",GSM2353647,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1228,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,multiple,Female,33.99726027,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 17,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.01,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.272,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353647/suppl/GSM2353647_A52084400940118100915421438150812.CEL.gz,0,Reanalyzed by: GSM2352185,NA,GSM2353647
GSM2353648_A52084400940103100915421438150734.CEL,"SUBJ.1228, SLE, week16",GSM2353648,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1228,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,multiple,Female,33.99726027,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 17,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.01,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.272,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353648/suppl/GSM2353648_A52084400940103100915421438150734.CEL.gz,0,,NA,GSM2353648
GSM2353649_A52084400940119100915421438150872.CEL,"SUBJ.1228, SLE, week52",GSM2353649,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1228,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,multiple,Female,33.99726027,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 17,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.01,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.272,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353649/suppl/GSM2353649_A52084400940119100915421438150872.CEL.gz,0,,NA,GSM2353649
GSM2353650_A52084400940143101215421438273162.CEL,"SUBJ.1298, SLE, week16",GSM2353650,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1298,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,57.53150685,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 6,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.33,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.183,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353650/suppl/GSM2353650_A52084400940143101215421438273162.CEL.gz,0,,NA,GSM2353650
GSM2353651_A52084400940141101215421438273108.CEL,"SUBJ.1298, SLE, week52",GSM2353651,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1298,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,57.53150685,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 6,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.33,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.183,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353651/suppl/GSM2353651_A52084400940141101215421438273108.CEL.gz,0,,NA,GSM2353651
GSM2353652_A52084400939702101515421439062129.CEL,"SUBJ.0774, SLE, baseline",GSM2353652,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0774,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,41.2109589,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.916,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.1,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353652/suppl/GSM2353652_A52084400939702101515421439062129.CEL.gz,0,Reanalyzed by: GSM2352294,NA,GSM2353652
GSM2353653_A52084400939410101115421438971302.CEL,"SUBJ.0774, SLE, week16",GSM2353653,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0774,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,41.2109589,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.916,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.1,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353653/suppl/GSM2353653_A52084400939410101115421438971302.CEL.gz,0,,NA,GSM2353653
GSM2353654_A52084400939410101115421438971314.CEL,"SUBJ.0774, SLE, week52",GSM2353654,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0774,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,41.2109589,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.916,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.1,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353654/suppl/GSM2353654_A52084400939410101115421438971314.CEL.gz,0,,NA,GSM2353654
GSM2353655_A52084400940083100815421437950534.CEL,"SUBJ.1520, SLE, baseline",GSM2353655,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1520,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,54.43835616,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.185,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353655/suppl/GSM2353655_A52084400940083100815421437950534.CEL.gz,0,Reanalyzed by: GSM2351178,NA,GSM2353655
GSM2353656_A52084400940082100815421437950473.CEL,"SUBJ.1520, SLE, week16",GSM2353656,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1520,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,54.43835616,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.185,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353656/suppl/GSM2353656_A52084400940082100815421437950473.CEL.gz,0,,NA,GSM2353656
GSM2353657_A52084400940080100815421437950343.CEL,"SUBJ.1520, SLE, week52",GSM2353657,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1520,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,54.43835616,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.185,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353657/suppl/GSM2353657_A52084400940080100815421437950343.CEL.gz,0,,NA,GSM2353657
GSM2353658_A52084400940083100815421437950536.CEL,"SUBJ.1706, SLE, baseline",GSM2353658,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1706,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,39.16712329,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.51,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353658/suppl/GSM2353658_A52084400940083100815421437950536.CEL.gz,0,Reanalyzed by: GSM2352045,NA,GSM2353658
GSM2353659_A52084400940081100815421437950410.CEL,"SUBJ.1706, SLE, week16",GSM2353659,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1706,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,39.16712329,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.51,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353659/suppl/GSM2353659_A52084400940081100815421437950410.CEL.gz,0,,NA,GSM2353659
GSM2353660_A52084400940080100815421437950350.CEL,"SUBJ.1706, SLE, week52",GSM2353660,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1706,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,39.16712329,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.51,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353660/suppl/GSM2353660_A52084400940080100815421437950350.CEL.gz,0,,NA,GSM2353660
GSM2353661_A52084400940070100715421373649400.CEL,"SUBJ.1383, SLE, baseline",GSM2353661,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1383,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,62.79781421,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.786,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353661/suppl/GSM2353661_A52084400940070100715421373649400.CEL.gz,0,Reanalyzed by: GSM2352380,NA,GSM2353661
GSM2353662_A52084400940068100715421373649299.CEL,"SUBJ.1383, SLE, week52",GSM2353662,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1383,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,62.79781421,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.786,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.136,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353662/suppl/GSM2353662_A52084400940068100715421373649299.CEL.gz,0,,NA,GSM2353662
GSM2353663_A52084400940728100515421373263897.CEL,"SUBJ.0332, SLE, baseline",GSM2353663,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0332,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,65.61369863,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.149,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353663/suppl/GSM2353663_A52084400940728100515421373263897.CEL.gz,0,Reanalyzed by: GSM2351874,NA,GSM2353663
GSM2353664_A52084400940726100515421373263764.CEL,"SUBJ.0332, SLE, week16",GSM2353664,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0332,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,65.61369863,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.149,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353664/suppl/GSM2353664_A52084400940726100515421373263764.CEL.gz,0,,NA,GSM2353664
GSM2353665_A52084400940726100515421373263762.CEL,"SUBJ.0332, SLE, week52",GSM2353665,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0332,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,65.61369863,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.149,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353665/suppl/GSM2353665_A52084400940726100515421373263762.CEL.gz,0,,NA,GSM2353665
GSM2353666_A52084400940081100815421437950379.CEL,"SUBJ.0520, SLE, baseline",GSM2353666,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0520,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,50.90410959,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 8,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.26,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.222,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353666/suppl/GSM2353666_A52084400940081100815421437950379.CEL.gz,0,Reanalyzed by: GSM2352023,NA,GSM2353666
GSM2353667_A52084400940081100815421437950404.CEL,"SUBJ.0520, SLE, week16",GSM2353667,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0520,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,50.90410959,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 8,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.26,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.222,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353667/suppl/GSM2353667_A52084400940081100815421437950404.CEL.gz,0,,NA,GSM2353667
GSM2353668_A52084400939411101115421438971377.CEL,"SUBJ.1123, SLE, baseline",GSM2353668,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1123,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,29.03013699,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.928,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.179,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353668/suppl/GSM2353668_A52084400939411101115421438971377.CEL.gz,0,Reanalyzed by: GSM2352173,NA,GSM2353668
GSM2353669_A52084400939409101115421438971246.CEL,"SUBJ.1123, SLE, week16",GSM2353669,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1123,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,29.03013699,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.928,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.179,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353669/suppl/GSM2353669_A52084400939409101115421438971246.CEL.gz,0,,NA,GSM2353669
GSM2353670_A52084400939411101115421438971409.CEL,"SUBJ.1123, SLE, week52",GSM2353670,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1123,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,29.03013699,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.928,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.179,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353670/suppl/GSM2353670_A52084400939411101115421438971409.CEL.gz,0,,NA,GSM2353670
GSM2353671_A52084400940119100915421438150875.CEL,"SUBJ.0555, SLE, baseline",GSM2353671,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0555,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,63.83606557,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 119,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.18,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.299,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353671/suppl/GSM2353671_A52084400940119100915421438150875.CEL.gz,0,Reanalyzed by: GSM2350966,NA,GSM2353671
GSM2353672_A52084400940119100915421438150837.CEL,"SUBJ.0555, SLE, week16",GSM2353672,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0555,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,63.83606557,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 119,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.18,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.299,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353672/suppl/GSM2353672_A52084400940119100915421438150837.CEL.gz,0,,NA,GSM2353672
GSM2353673_A52084400940119100915421438150841.CEL,"SUBJ.0555, SLE, week52",GSM2353673,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0555,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,63.83606557,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 119,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.18,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.299,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353673/suppl/GSM2353673_A52084400940119100915421438150841.CEL.gz,0,,NA,GSM2353673
GSM2353674_A52084400939559101515421438861390.CEL,"SUBJ.1042, SLE, baseline",GSM2353674,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1042,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,54.99452055,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 65,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.27,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.099,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353674/suppl/GSM2353674_A52084400939559101515421438861390.CEL.gz,0,Reanalyzed by: GSM2352321,NA,GSM2353674
GSM2353675_A52084400939705101515421439062328.CEL,"SUBJ.1042, SLE, week16",GSM2353675,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1042,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,54.99452055,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 65,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.27,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.099,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353675/suppl/GSM2353675_A52084400939705101515421439062328.CEL.gz,0,,NA,GSM2353675
GSM2353676_A52084400939704101515421439062244.CEL,"SUBJ.1042, SLE, week52",GSM2353676,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1042,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,54.99452055,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 65,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.27,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.099,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353676/suppl/GSM2353676_A52084400939704101515421439062244.CEL.gz,0,,NA,GSM2353676
GSM2353677_A52084400940070100715421373649407.CEL,"SUBJ.0245, SLE, baseline",GSM2353677,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0245,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,28.9369863,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 10,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.35,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.226,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353677/suppl/GSM2353677_A52084400940070100715421373649407.CEL.gz,0,Reanalyzed by: GSM2352279,NA,GSM2353677
GSM2353678_A52084400940068100715421373649282.CEL,"SUBJ.0245, SLE, week52",GSM2353678,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0245,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,28.9369863,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 10,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.35,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.226,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353678/suppl/GSM2353678_A52084400940068100715421373649282.CEL.gz,0,,NA,GSM2353678
GSM2353679_A52084400939495101415421438760364.CEL,"SUBJ.1428, SLE, baseline",GSM2353679,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1428,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,47.86575342,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.157,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353679/suppl/GSM2353679_A52084400939495101415421438760364.CEL.gz,0,Reanalyzed by: GSM2351898,NA,GSM2353679
GSM2353680_A52084400939497101415421438760457.CEL,"SUBJ.1428, SLE, week16",GSM2353680,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1428,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,47.86575342,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.157,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353680/suppl/GSM2353680_A52084400939497101415421438760457.CEL.gz,0,,NA,GSM2353680
GSM2353681_A52084400939495101415421438760342.CEL,"SUBJ.1428, SLE, week52",GSM2353681,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1428,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,47.86575342,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.157,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353681/suppl/GSM2353681_A52084400939495101415421438760342.CEL.gz,0,,NA,GSM2353681
GSM2353682_A52084400940069100715421373649347.CEL,"SUBJ.0941, SLE, baseline",GSM2353682,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0941,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,46.07671233,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.269,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353682/suppl/GSM2353682_A52084400940069100715421373649347.CEL.gz,0,Reanalyzed by: GSM2351057,NA,GSM2353682
GSM2353683_A52084400940067100715421373649251.CEL,"SUBJ.0941, SLE, week16",GSM2353683,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0941,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,46.07671233,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.269,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353683/suppl/GSM2353683_A52084400940067100715421373649251.CEL.gz,0,,NA,GSM2353683
GSM2353684_A52084400940070100715421373649413.CEL,"SUBJ.0941, SLE, week52",GSM2353684,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0941,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,46.07671233,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.269,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353684/suppl/GSM2353684_A52084400940070100715421373649413.CEL.gz,0,,NA,GSM2353684
GSM2353685_A52084400940082100815421437950451.CEL,"SUBJ.0089, SLE, baseline",GSM2353685,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0089,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,57.96448087,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 73,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.801,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.107,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353685/suppl/GSM2353685_A52084400940082100815421437950451.CEL.gz,0,Reanalyzed by: GSM2351059,NA,GSM2353685
GSM2353686_A52084400940083100815421437950506.CEL,"SUBJ.0089, SLE, week16",GSM2353686,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0089,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,57.96448087,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 73,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.801,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.107,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353686/suppl/GSM2353686_A52084400940083100815421437950506.CEL.gz,0,,NA,GSM2353686
GSM2353687_A52084400940080100815421437950347.CEL,"SUBJ.0089, SLE, week52",GSM2353687,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0089,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,57.96448087,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 73,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.801,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.107,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353687/suppl/GSM2353687_A52084400940080100815421437950347.CEL.gz,0,,NA,GSM2353687
GSM2353688_A52084400940728100515421373263860.CEL,"SUBJ.1753, SLE, baseline",GSM2353688,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1753,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,57.09041096,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 149,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.03,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.185,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353688/suppl/GSM2353688_A52084400940728100515421373263860.CEL.gz,0,Reanalyzed by: GSM2351573,NA,GSM2353688
GSM2353689_A52084400940080100815421437950321.CEL,"SUBJ.1753, SLE, week16",GSM2353689,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1753,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,57.09041096,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 149,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.03,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.185,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353689/suppl/GSM2353689_A52084400940080100815421437950321.CEL.gz,0,,NA,GSM2353689
GSM2353690_A52084400940728100515421373263876.CEL,"SUBJ.1753, SLE, week52",GSM2353690,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1753,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,57.09041096,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 149,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.03,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.185,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353690/suppl/GSM2353690_A52084400940728100515421373263876.CEL.gz,0,,NA,GSM2353690
GSM2353691_A52084400939559101515421438861371.CEL,"SUBJ.0204, SLE, baseline",GSM2353691,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0204,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,46.29589041,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 50,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.06,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.103,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353691/suppl/GSM2353691_A52084400939559101515421438861371.CEL.gz,0,Reanalyzed by: GSM2352451,NA,GSM2353691
GSM2353692_A52084400939561101515421438861485.CEL,"SUBJ.0204, SLE, week16",GSM2353692,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0204,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,46.29589041,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 50,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.06,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.103,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353692/suppl/GSM2353692_A52084400939561101515421438861485.CEL.gz,0,,NA,GSM2353692
GSM2353693_A52084400939560101515421438861421.CEL,"SUBJ.0204, SLE, week52",GSM2353693,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0204,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,46.29589041,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 50,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.06,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.103,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353693/suppl/GSM2353693_A52084400939560101515421438861421.CEL.gz,0,,NA,GSM2353693
GSM2353694_A52084400939558101515421438861343.CEL,"SUBJ.0670, SLE, baseline",GSM2353694,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0670,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,30.81420765,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 150,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.821,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.093,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353694/suppl/GSM2353694_A52084400939558101515421438861343.CEL.gz,0,Reanalyzed by: GSM2351018,NA,GSM2353694
GSM2353695_A52084400939560101515421438861452.CEL,"SUBJ.0670, SLE, week16",GSM2353695,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0670,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,30.81420765,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 150,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.821,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.093,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353695/suppl/GSM2353695_A52084400939560101515421438861452.CEL.gz,0,,NA,GSM2353695
GSM2353696_A52084400939558101515421438861335.CEL,"SUBJ.0670, SLE, week52",GSM2353696,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0670,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,30.81420765,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 150,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.821,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.093,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353696/suppl/GSM2353696_A52084400939558101515421438861335.CEL.gz,0,,NA,GSM2353696
GSM2353697_A52084400940728100515421373263882.CEL,"SUBJ.0107, SLE, baseline",GSM2353697,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0107,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,25.72328767,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.899,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.106,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353697/suppl/GSM2353697_A52084400940728100515421373263882.CEL.gz,0,Reanalyzed by: GSM2352408,NA,GSM2353697
GSM2353698_A52084400940727100515421373263795.CEL,"SUBJ.0107, SLE, week16",GSM2353698,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0107,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,25.72328767,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.899,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.106,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353698/suppl/GSM2353698_A52084400940727100515421373263795.CEL.gz,0,,NA,GSM2353698
GSM2353699_A52084400940728100515421373263886.CEL,"SUBJ.0107, SLE, week52",GSM2353699,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0107,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,25.72328767,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.899,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.106,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353699/suppl/GSM2353699_A52084400940728100515421373263886.CEL.gz,0,,NA,GSM2353699
GSM2353700_A52084400940143101215421438273157.CEL,"SUBJ.1048, SLE, baseline",GSM2353700,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1048,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,62.85519126,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 76,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.188,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353700/suppl/GSM2353700_A52084400940143101215421438273157.CEL.gz,0,Reanalyzed by: GSM2351264,NA,GSM2353700
GSM2353701_A52084400939559101515421438861394.CEL,"SUBJ.1048, SLE, week16",GSM2353701,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1048,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,62.85519126,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 76,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.188,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353701/suppl/GSM2353701_A52084400939559101515421438861394.CEL.gz,0,,NA,GSM2353701
GSM2353702_A52084400940141101215421438273092.CEL,"SUBJ.1048, SLE, week52",GSM2353702,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1048,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,62.85519126,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 76,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.188,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353702/suppl/GSM2353702_A52084400940141101215421438273092.CEL.gz,0,,NA,GSM2353702
GSM2353703_A52084400940726100515421373263773.CEL,"SUBJ.1641, SLE, baseline",GSM2353703,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1641,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,52.08767123,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.834,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.191,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353703/suppl/GSM2353703_A52084400940726100515421373263773.CEL.gz,0,Reanalyzed by: GSM2352039,NA,GSM2353703
GSM2353704_A52084400940083100815421437950531.CEL,"SUBJ.1641, SLE, week16",GSM2353704,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1641,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,52.08767123,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.834,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.191,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353704/suppl/GSM2353704_A52084400940083100815421437950531.CEL.gz,0,,NA,GSM2353704
GSM2353705_A52084400940728100515421373263864.CEL,"SUBJ.1641, SLE, week52",GSM2353705,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1641,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,52.08767123,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.834,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.191,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353705/suppl/GSM2353705_A52084400940728100515421373263864.CEL.gz,0,,NA,GSM2353705
GSM2353706_A52084400940081100815421437950425.CEL,"SUBJ.1167, SLE, baseline",GSM2353706,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1167,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,50.96986301,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 166,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.338,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353706/suppl/GSM2353706_A52084400940081100815421437950425.CEL.gz,0,Reanalyzed by: GSM2351386,NA,GSM2353706
GSM2353707_A52084400940080100815421437950363.CEL,"SUBJ.1167, SLE, week16",GSM2353707,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1167,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,50.96986301,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 166,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.338,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353707/suppl/GSM2353707_A52084400940080100815421437950363.CEL.gz,0,,NA,GSM2353707
GSM2353708_A52084400940083100815421437950520.CEL,"SUBJ.1167, SLE, week52",GSM2353708,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1167,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,50.96986301,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 166,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.338,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353708/suppl/GSM2353708_A52084400940083100815421437950520.CEL.gz,0,,NA,GSM2353708
GSM2353709_A52084400940119100915421438150829.CEL,"SUBJ.0380, SLE, baseline",GSM2353709,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0380,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,38.91506849,us_can,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 227,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.14,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.235,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353709/suppl/GSM2353709_A52084400940119100915421438150829.CEL.gz,0,Reanalyzed by: GSM2352132,NA,GSM2353709
GSM2353710_A52084400940119100915421438150840.CEL,"SUBJ.0380, SLE, week16",GSM2353710,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0380,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,38.91506849,us_can,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 227,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.14,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.235,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353710/suppl/GSM2353710_A52084400940119100915421438150840.CEL.gz,0,,NA,GSM2353710
GSM2353711_A52084400940068100715421373649272.CEL,"SUBJ.0380, SLE, week52",GSM2353711,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0380,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,38.91506849,us_can,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 227,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.14,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.235,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353711/suppl/GSM2353711_A52084400940068100715421373649272.CEL.gz,0,,NA,GSM2353711
GSM2353712_A52084400939410101115421438971300.CEL,"SUBJ.0562, SLE, baseline",GSM2353712,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0562,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,38.21917808,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.74,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.316,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353712/suppl/GSM2353712_A52084400939410101115421438971300.CEL.gz,0,Reanalyzed by: GSM2351633,NA,GSM2353712
GSM2353713_A52084400939410101115421438971332.CEL,"SUBJ.0562, SLE, week52",GSM2353713,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0562,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,38.21917808,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.74,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.316,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353713/suppl/GSM2353713_A52084400939410101115421438971332.CEL.gz,0,,NA,GSM2353713
GSM2353714_A52084400940102100915421438150697.CEL,"SUBJ.1621, SLE, baseline",GSM2353714,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1621,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,56.84657534,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.36,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.351,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353714/suppl/GSM2353714_A52084400940102100915421438150697.CEL.gz,0,Reanalyzed by: GSM2352310,NA,GSM2353714
GSM2353715_A52084400940102100915421438150650.CEL,"SUBJ.1621, SLE, week16",GSM2353715,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1621,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,56.84657534,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.36,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.351,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353715/suppl/GSM2353715_A52084400940102100915421438150650.CEL.gz,0,,NA,GSM2353715
GSM2353716_A52084400940103100915421438150749.CEL,"SUBJ.1621, SLE, week52",GSM2353716,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1621,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,56.84657534,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.36,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.351,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353716/suppl/GSM2353716_A52084400940103100915421438150749.CEL.gz,0,,NA,GSM2353716
GSM2353717_A52084400940082100815421437950466.CEL,"SUBJ.1285, SLE, baseline",GSM2353717,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1285,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,67.28767123,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 24,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.27,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353717/suppl/GSM2353717_A52084400940082100815421437950466.CEL.gz,0,Reanalyzed by: GSM2351551,NA,GSM2353717
GSM2353718_A52084400940082100815421437950465.CEL,"SUBJ.1285, SLE, week16",GSM2353718,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1285,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,67.28767123,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 24,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.27,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353718/suppl/GSM2353718_A52084400940082100815421437950465.CEL.gz,0,,NA,GSM2353718
GSM2353719_A52084400940080100815421437950351.CEL,"SUBJ.1285, SLE, week52",GSM2353719,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1285,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,67.28767123,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 24,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.27,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353719/suppl/GSM2353719_A52084400940080100815421437950351.CEL.gz,0,,NA,GSM2353719
GSM2353720_A52084400939472101415421438760268.CEL,"SUBJ.0213, SLE, baseline",GSM2353720,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0213,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.98082192,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.109,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353720/suppl/GSM2353720_A52084400939472101415421438760268.CEL.gz,0,Reanalyzed by: GSM2352440,NA,GSM2353720
GSM2353721_A52084400939495101415421438760332.CEL,"SUBJ.0213, SLE, week16",GSM2353721,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0213,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.98082192,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.109,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353721/suppl/GSM2353721_A52084400939495101415421438760332.CEL.gz,0,,NA,GSM2353721
GSM2353722_A52084400940140101215421438273053.CEL,"SUBJ.0213, SLE, week52",GSM2353722,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0213,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.98082192,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.109,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353722/suppl/GSM2353722_A52084400940140101215421438273053.CEL.gz,0,,NA,GSM2353722
GSM2353723_A52084400940118100915421438150786.CEL,"SUBJ.0393, SLE, week16",GSM2353723,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0393,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,38.73497268,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 99,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.723,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.234,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353723/suppl/GSM2353723_A52084400940118100915421438150786.CEL.gz,0,,NA,GSM2353723
GSM2353724_A52084400940102100915421438150662.CEL,"SUBJ.0393, SLE, week52",GSM2353724,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0393,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,38.73497268,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 99,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.723,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.234,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353724/suppl/GSM2353724_A52084400940102100915421438150662.CEL.gz,0,,NA,GSM2353724
GSM2353725_A52084400940067100715421373649221.CEL,"SUBJ.1436, SLE, baseline",GSM2353725,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1436,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.00547945,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 111,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.851,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353725/suppl/GSM2353725_A52084400940067100715421373649221.CEL.gz,0,Reanalyzed by: GSM2352119,NA,GSM2353725
GSM2353726_A52084400940069100715421373649353.CEL,"SUBJ.1436, SLE, week16",GSM2353726,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1436,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.00547945,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 111,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.851,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353726/suppl/GSM2353726_A52084400940069100715421373649353.CEL.gz,0,,NA,GSM2353726
GSM2353727_A52084400940070100715421373649416.CEL,"SUBJ.1436, SLE, week52",GSM2353727,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1436,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.00547945,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 111,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.851,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353727/suppl/GSM2353727_A52084400940070100715421373649416.CEL.gz,0,,NA,GSM2353727
GSM2353728_A52084400939412101115421438971500.CEL,"SUBJ.0225, SLE, baseline",GSM2353728,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0225,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,49.24383562,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.803,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.189,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353728/suppl/GSM2353728_A52084400939412101115421438971500.CEL.gz,0,Reanalyzed by: GSM2351297,NA,GSM2353728
GSM2353729_A52084400939409101115421438971252.CEL,"SUBJ.0225, SLE, week16",GSM2353729,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0225,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,49.24383562,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.803,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.189,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353729/suppl/GSM2353729_A52084400939409101115421438971252.CEL.gz,0,,NA,GSM2353729
GSM2353730_A52084400939412101115421438971516.CEL,"SUBJ.0225, SLE, week52",GSM2353730,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0225,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,49.24383562,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.803,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.189,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353730/suppl/GSM2353730_A52084400939412101115421438971516.CEL.gz,0,,NA,GSM2353730
GSM2353731_A52084400940143101215421438273145.CEL,"SUBJ.1399, SLE, baseline",GSM2353731,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1399,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.4109589,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.705,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.13,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353731/suppl/GSM2353731_A52084400940143101215421438273145.CEL.gz,0,Reanalyzed by: GSM2351670,NA,GSM2353731
GSM2353732_A52084400940143101215421438273163.CEL,"SUBJ.1399, SLE, week16",GSM2353732,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1399,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.4109589,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.705,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.13,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353732/suppl/GSM2353732_A52084400940143101215421438273163.CEL.gz,0,,NA,GSM2353732
GSM2353733_A52084400940144101215421438273212.CEL,"SUBJ.1399, SLE, week52",GSM2353733,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1399,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.4109589,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.705,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.13,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353733/suppl/GSM2353733_A52084400940144101215421438273212.CEL.gz,0,,NA,GSM2353733
GSM2353734_A52084400940082100815421437950475.CEL,"SUBJ.0057, SLE, baseline",GSM2353734,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0057,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,45.81693989,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.65,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353734/suppl/GSM2353734_A52084400940082100815421437950475.CEL.gz,0,Reanalyzed by: GSM2351427,NA,GSM2353734
GSM2353735_A52084400940729100515421373263931.CEL,"SUBJ.0057, SLE, week16",GSM2353735,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0057,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,45.81693989,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.65,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353735/suppl/GSM2353735_A52084400940729100515421373263931.CEL.gz,0,,NA,GSM2353735
GSM2353736_A52084400940727100515421373263822.CEL,"SUBJ.0057, SLE, week52",GSM2353736,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0057,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,45.81693989,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.65,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353736/suppl/GSM2353736_A52084400940727100515421373263822.CEL.gz,0,,NA,GSM2353736
GSM2353737_A52084400939561101515421438861498.CEL,"SUBJ.0552, SLE, baseline",GSM2353737,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0552,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,31.97260274,us_can,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.883,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.132,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353737/suppl/GSM2353737_A52084400939561101515421438861498.CEL.gz,0,Reanalyzed by: GSM2351916,NA,GSM2353737
GSM2353738_A52084400939560101515421438861462.CEL,"SUBJ.0552, SLE, week16",GSM2353738,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0552,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,31.97260274,us_can,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.883,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.132,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353738/suppl/GSM2353738_A52084400939560101515421438861462.CEL.gz,0,,NA,GSM2353738
GSM2353739_A52084400939560101515421438861447.CEL,"SUBJ.0552, SLE, week52",GSM2353739,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0552,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,31.97260274,us_can,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.883,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.132,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353739/suppl/GSM2353739_A52084400939560101515421438861447.CEL.gz,0,,NA,GSM2353739
GSM2353740_A52084400939412101115421438971515.CEL,"SUBJ.0690, SLE, baseline",GSM2353740,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0690,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,63.19178082,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.42,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.282,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353740/suppl/GSM2353740_A52084400939412101115421438971515.CEL.gz,0,Reanalyzed by: GSM2351346,NA,GSM2353740
GSM2353741_A52084400939702101515421439062122.CEL,"SUBJ.0690, SLE, week52",GSM2353741,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0690,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,63.19178082,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.42,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.282,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353741/suppl/GSM2353741_A52084400939702101515421439062122.CEL.gz,0,,NA,GSM2353741
GSM2353742_A52084400940141101215421438273430.CEL,"SUBJ.0266, SLE, baseline",GSM2353742,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0266,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,32.8579235,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 13,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.182,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353742/suppl/GSM2353742_A52084400940141101215421438273430.CEL.gz,0,Reanalyzed by: GSM2352597,NA,GSM2353742
GSM2353743_A52084400940141101215421438273096.CEL,"SUBJ.0266, SLE, week16",GSM2353743,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0266,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,32.8579235,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 13,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.182,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353743/suppl/GSM2353743_A52084400940141101215421438273096.CEL.gz,0,,NA,GSM2353743
GSM2353744_A52084400939496101415421438760425.CEL,"SUBJ.0266, SLE, week52",GSM2353744,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0266,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,32.8579235,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 13,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.182,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353744/suppl/GSM2353744_A52084400939496101415421438760425.CEL.gz,0,,NA,GSM2353744
GSM2353745_A52084400939704101515421439062255.CEL,"SUBJ.0756, SLE, baseline",GSM2353745,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0756,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,amer_ind_ak_native,Female,40.35616438,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.02,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.182,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353745/suppl/GSM2353745_A52084400939704101515421439062255.CEL.gz,0,Reanalyzed by: GSM2351250,NA,GSM2353745
GSM2353746_A52084400939702101515421439062117.CEL,"SUBJ.0756, SLE, week16",GSM2353746,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0756,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,amer_ind_ak_native,Female,40.35616438,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.02,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.182,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353746/suppl/GSM2353746_A52084400939702101515421439062117.CEL.gz,0,,NA,GSM2353746
GSM2353747_A52084400939412101115421438971497.CEL,"SUBJ.0756, SLE, week52",GSM2353747,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0756,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,amer_ind_ak_native,Female,40.35616438,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.02,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.182,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353747/suppl/GSM2353747_A52084400939412101115421438971497.CEL.gz,0,,NA,GSM2353747
GSM2353748_A52084400940083100815421437950530.CEL,"SUBJ.1652, SLE, baseline",GSM2353748,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1652,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,38.97260274,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 89,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.664,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.08,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353748/suppl/GSM2353748_A52084400940083100815421437950530.CEL.gz,0,Reanalyzed by: GSM2352209,NA,GSM2353748
GSM2353749_A52084400940082100815421437950483.CEL,"SUBJ.1652, SLE, week16",GSM2353749,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1652,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,38.97260274,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 89,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.664,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.08,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353749/suppl/GSM2353749_A52084400940082100815421437950483.CEL.gz,0,,NA,GSM2353749
GSM2353750_A52084400940069100715421373649370.CEL,"SUBJ.1652, SLE, week52",GSM2353750,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1652,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,38.97260274,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 89,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.664,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.08,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353750/suppl/GSM2353750_A52084400940069100715421373649370.CEL.gz,0,,NA,GSM2353750
GSM2353751_A52084400940069100715421373649338.CEL,"SUBJ.0313, SLE, baseline",GSM2353751,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0313,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,42.24383562,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.293,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353751/suppl/GSM2353751_A52084400940069100715421373649338.CEL.gz,0,Reanalyzed by: GSM2352061,NA,GSM2353751
GSM2353752_A52084400940070100715421373649419.CEL,"SUBJ.0313, SLE, week16",GSM2353752,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0313,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,42.24383562,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.293,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353752/suppl/GSM2353752_A52084400940070100715421373649419.CEL.gz,0,,NA,GSM2353752
GSM2353753_A52084400940069100715421373649336.CEL,"SUBJ.0313, SLE, week52",GSM2353753,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0313,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,42.24383562,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.293,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353753/suppl/GSM2353753_A52084400940069100715421373649336.CEL.gz,0,,NA,GSM2353753
GSM2353754_A52084400939560101515421438861437.CEL,"SUBJ.0695, SLE, baseline",GSM2353754,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0695,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,42.39178082,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 128,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.01,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.191,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353754/suppl/GSM2353754_A52084400939560101515421438861437.CEL.gz,0,Reanalyzed by: GSM2352224,NA,GSM2353754
GSM2353755_A52084400939703101515421439062206.CEL,"SUBJ.0695, SLE, week16",GSM2353755,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0695,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,42.39178082,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 128,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.01,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.191,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353755/suppl/GSM2353755_A52084400939703101515421439062206.CEL.gz,0,,NA,GSM2353755
GSM2353756_A52084400939702101515421439062120.CEL,"SUBJ.0695, SLE, week52",GSM2353756,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0695,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,42.39178082,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 128,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.01,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.191,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353756/suppl/GSM2353756_A52084400939702101515421439062120.CEL.gz,0,,NA,GSM2353756
GSM2353757_A52084400940118100915421438150813.CEL,"SUBJ.1441, SLE, baseline",GSM2353757,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1441,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,64.83835616,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.873,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353757/suppl/GSM2353757_A52084400940118100915421438150813.CEL.gz,0,Reanalyzed by: GSM2352351,NA,GSM2353757
GSM2353758_A52084400940119100915421438150834.CEL,"SUBJ.1441, SLE, week16",GSM2353758,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1441,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,64.83835616,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.873,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353758/suppl/GSM2353758_A52084400940119100915421438150834.CEL.gz,0,,NA,GSM2353758
GSM2353759_A52084400940119100915421438150852.CEL,"SUBJ.1441, SLE, week52",GSM2353759,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1441,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,64.83835616,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.873,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353759/suppl/GSM2353759_A52084400940119100915421438150852.CEL.gz,0,,NA,GSM2353759
GSM2353760_A52084400940727100515421373263820.CEL,"SUBJ.1381, SLE, baseline",GSM2353760,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1381,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,45.46027397,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.24,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.237,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353760/suppl/GSM2353760_A52084400940727100515421373263820.CEL.gz,0,Reanalyzed by: GSM2351729,NA,GSM2353760
GSM2353761_A52084400940727100515421373263809.CEL,"SUBJ.1381, SLE, week16",GSM2353761,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1381,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,45.46027397,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.24,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.237,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353761/suppl/GSM2353761_A52084400940727100515421373263809.CEL.gz,0,,NA,GSM2353761
GSM2353762_A52084400940082100815421437950487.CEL,"SUBJ.1381, SLE, week52",GSM2353762,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1381,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,45.46027397,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.24,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.237,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353762/suppl/GSM2353762_A52084400940082100815421437950487.CEL.gz,0,,NA,GSM2353762
GSM2353763_A52084400940119100915421438150853.CEL,"SUBJ.0979, SLE, baseline",GSM2353763,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0979,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.89589041,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 52,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.02,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.169,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353763/suppl/GSM2353763_A52084400940119100915421438150853.CEL.gz,0,Reanalyzed by: GSM2351807,NA,GSM2353763
GSM2353764_A52084400940118100915421438150791.CEL,"SUBJ.0979, SLE, week16",GSM2353764,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0979,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.89589041,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 52,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.02,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.169,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353764/suppl/GSM2353764_A52084400940118100915421438150791.CEL.gz,0,,NA,GSM2353764
GSM2353765_A52084400940070100715421373649424.CEL,"SUBJ.0979, SLE, week52",GSM2353765,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0979,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.89589041,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 52,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.02,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.169,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353765/suppl/GSM2353765_A52084400940070100715421373649424.CEL.gz,0,,NA,GSM2353765
GSM2353766_A52084400940069100715421373649348.CEL,"SUBJ.0440, SLE, baseline",GSM2353766,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0440,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,22.89589041,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 49,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.234,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353766/suppl/GSM2353766_A52084400940069100715421373649348.CEL.gz,0,Reanalyzed by: GSM2351008,NA,GSM2353766
GSM2353767_A52084400940069100715421373649335.CEL,"SUBJ.0440, SLE, week52",GSM2353767,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0440,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,22.89589041,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 49,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.234,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353767/suppl/GSM2353767_A52084400940069100715421373649335.CEL.gz,0,,NA,GSM2353767
GSM2353768_A52084400940728100515421373263855.CEL,"SUBJ.0284, SLE, baseline",GSM2353768,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0284,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,54.20273973,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.896,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.106,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353768/suppl/GSM2353768_A52084400940728100515421373263855.CEL.gz,0,Reanalyzed by: GSM2351832,NA,GSM2353768
GSM2353769_A52084400940729100515421373263943.CEL,"SUBJ.0284, SLE, week16",GSM2353769,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0284,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,54.20273973,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.896,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.106,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353769/suppl/GSM2353769_A52084400940729100515421373263943.CEL.gz,0,,NA,GSM2353769
GSM2353770_A52084400940726100515421373263770.CEL,"SUBJ.0284, SLE, week52",GSM2353770,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0284,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,54.20273973,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.896,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.106,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353770/suppl/GSM2353770_A52084400940726100515421373263770.CEL.gz,0,,NA,GSM2353770
GSM2353771_A52084400939560101515421438861436.CEL,"SUBJ.1438, SLE, baseline",GSM2353771,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1438,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,35.28493151,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.58,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.07,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353771/suppl/GSM2353771_A52084400939560101515421438861436.CEL.gz,0,Reanalyzed by: GSM2352649,NA,GSM2353771
GSM2353772_A52084400939561101515421438861501.CEL,"SUBJ.1438, SLE, week16",GSM2353772,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1438,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,35.28493151,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.58,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.07,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353772/suppl/GSM2353772_A52084400939561101515421438861501.CEL.gz,0,,NA,GSM2353772
GSM2353773_A52084400939560101515421438861422.CEL,"SUBJ.1438, SLE, week52",GSM2353773,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1438,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,35.28493151,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.58,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.07,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353773/suppl/GSM2353773_A52084400939560101515421438861422.CEL.gz,0,,NA,GSM2353773
GSM2353774_A52084400939559101515421438861387.CEL,"SUBJ.0663, SLE, baseline",GSM2353774,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0663,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,62.27671233,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.959,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353774/suppl/GSM2353774_A52084400939559101515421438861387.CEL.gz,0,Reanalyzed by: GSM2351278,NA,GSM2353774
GSM2353775_A52084400939410101115421438971327.CEL,"SUBJ.0663, SLE, week16",GSM2353775,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0663,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,62.27671233,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.959,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353775/suppl/GSM2353775_A52084400939410101115421438971327.CEL.gz,0,,NA,GSM2353775
GSM2353776_A52084400939409101115421438971273.CEL,"SUBJ.0663, SLE, week52",GSM2353776,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0663,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,62.27671233,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.959,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353776/suppl/GSM2353776_A52084400939409101115421438971273.CEL.gz,0,,NA,GSM2353776
GSM2353777_A52084400939495101415421438760328.CEL,"SUBJ.1776, SLE, baseline",GSM2353777,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1776,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Male,40.66939891,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.5,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.306,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353777/suppl/GSM2353777_A52084400939495101415421438760328.CEL.gz,0,Reanalyzed by: GSM2352441,NA,GSM2353777
GSM2353778_A52084400939472101415421438760313.CEL,"SUBJ.1776, SLE, week16",GSM2353778,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1776,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Male,40.66939891,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.5,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.306,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353778/suppl/GSM2353778_A52084400939472101415421438760313.CEL.gz,0,,NA,GSM2353778
GSM2353779_A52084400939412101115421438971480.CEL,"SUBJ.1776, SLE, week52",GSM2353779,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1776,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Male,40.66939891,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.5,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.306,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353779/suppl/GSM2353779_A52084400939412101115421438971480.CEL.gz,0,,NA,GSM2353779
GSM2353780_A52084400939472101415421438760310.CEL,"SUBJ.0496, SLE, baseline",GSM2353780,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0496,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,59.07671233,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.958,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.165,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353780/suppl/GSM2353780_A52084400939472101415421438760310.CEL.gz,0,Reanalyzed by: GSM2351764,NA,GSM2353780
GSM2353781_A52084400939409101115421438971265.CEL,"SUBJ.0496, SLE, week16",GSM2353781,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0496,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,59.07671233,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.958,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.165,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353781/suppl/GSM2353781_A52084400939409101115421438971265.CEL.gz,0,,NA,GSM2353781
GSM2353782_A52084400939410101115421438971346.CEL,"SUBJ.0496, SLE, week52",GSM2353782,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0496,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,59.07671233,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.958,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.165,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353782/suppl/GSM2353782_A52084400939410101115421438971346.CEL.gz,0,,NA,GSM2353782
GSM2353783_A52084400939412101115421438971523.CEL,"SUBJ.1250, SLE, baseline",GSM2353783,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1250,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,44.45479452,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.619,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.187,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353783/suppl/GSM2353783_A52084400939412101115421438971523.CEL.gz,0,Reanalyzed by: GSM2352054,NA,GSM2353783
GSM2353784_A52084400939412101115421438971520.CEL,"SUBJ.1250, SLE, week16",GSM2353784,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1250,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,44.45479452,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.619,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.187,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353784/suppl/GSM2353784_A52084400939412101115421438971520.CEL.gz,0,,NA,GSM2353784
GSM2353785_A52084400939703101515421439062186.CEL,"SUBJ.1250, SLE, week52",GSM2353785,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1250,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,44.45479452,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.619,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.187,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353785/suppl/GSM2353785_A52084400939703101515421439062186.CEL.gz,0,,NA,GSM2353785
GSM2353786_A52084400940068100715421373649308.CEL,"SUBJ.1483, SLE, baseline",GSM2353786,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1483,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,43.20547945,us_can,26,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H,c3_at_baseline (g/l): 1.89,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.09,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353786/suppl/GSM2353786_A52084400940068100715421373649308.CEL.gz,0,Reanalyzed by: GSM2351079,NA,GSM2353786
GSM2353787_A52084400940067100715421373649223.CEL,"SUBJ.1483, SLE, week16",GSM2353787,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1483,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,43.20547945,us_can,26,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H,c3_at_baseline (g/l): 1.89,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.09,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353787/suppl/GSM2353787_A52084400940067100715421373649223.CEL.gz,0,,NA,GSM2353787
GSM2353788_A52084400940068100715421373649315.CEL,"SUBJ.1483, SLE, week52",GSM2353788,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1483,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,43.20547945,us_can,26,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H,c3_at_baseline (g/l): 1.89,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.09,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353788/suppl/GSM2353788_A52084400940068100715421373649315.CEL.gz,0,,NA,GSM2353788
GSM2353789_A52084400939705101515421439062309.CEL,"SUBJ.0658, SLE, baseline",GSM2353789,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0658,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,37.97534247,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.802,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.096,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353789/suppl/GSM2353789_A52084400939705101515421439062309.CEL.gz,0,Reanalyzed by: GSM2351192,NA,GSM2353789
GSM2353790_A52084400940144101215421438273226.CEL,"SUBJ.0658, SLE, week16",GSM2353790,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0658,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,37.97534247,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.802,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.096,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353790/suppl/GSM2353790_A52084400940144101215421438273226.CEL.gz,0,,NA,GSM2353790
GSM2353791_A52084400940103100915421438150751.CEL,"SUBJ.0658, SLE, week52",GSM2353791,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0658,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,37.97534247,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.802,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.096,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353791/suppl/GSM2353791_A52084400940103100915421438150751.CEL.gz,0,,NA,GSM2353791
GSM2353792_A52084400939410101115421438971309.CEL,"SUBJ.1049, SLE, baseline",GSM2353792,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1049,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,multiple,Female,41.38082192,mex_ca_sa,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 63,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.672,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.111,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353792/suppl/GSM2353792_A52084400939410101115421438971309.CEL.gz,0,Reanalyzed by: GSM2352424,NA,GSM2353792
GSM2353793_A52084400939472101415421438775717.CEL,"SUBJ.1049, SLE, week16",GSM2353793,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1049,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,multiple,Female,41.38082192,mex_ca_sa,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 63,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.672,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.111,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353793/suppl/GSM2353793_A52084400939472101415421438775717.CEL.gz,0,,NA,GSM2353793
GSM2353794_A52084400939472101415421438760292.CEL,"SUBJ.1049, SLE, week52",GSM2353794,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1049,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,multiple,Female,41.38082192,mex_ca_sa,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 63,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.672,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.111,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353794/suppl/GSM2353794_A52084400939472101415421438760292.CEL.gz,0,,NA,GSM2353794
GSM2353795_A52084400939559101515421438861375.CEL,"SUBJ.0441, SLE, baseline",GSM2353795,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0441,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,19.95616438,us_can,7,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 211,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.626,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.077,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353795/suppl/GSM2353795_A52084400939559101515421438861375.CEL.gz,0,Reanalyzed by: GSM2351897,NA,GSM2353795
GSM2353796_A52084400939561101515421438861526.CEL,"SUBJ.0441, SLE, week16",GSM2353796,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0441,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,19.95616438,us_can,7,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 211,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.626,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.077,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353796/suppl/GSM2353796_A52084400939561101515421438861526.CEL.gz,0,,NA,GSM2353796
GSM2353797_A52084400939409101115421438971277.CEL,"SUBJ.0441, SLE, week52",GSM2353797,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0441,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,19.95616438,us_can,7,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 211,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.626,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.077,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353797/suppl/GSM2353797_A52084400939409101115421438971277.CEL.gz,0,,NA,GSM2353797
GSM2353798_A52084400940728100515421373263867.CEL,"SUBJ.0349, SLE, baseline",GSM2353798,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0349,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,38.10410959,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 111,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.135,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353798/suppl/GSM2353798_A52084400940728100515421373263867.CEL.gz,0,Reanalyzed by: GSM2351514,NA,GSM2353798
GSM2353799_A52084400940728100515421373263889.CEL,"SUBJ.0349, SLE, week16",GSM2353799,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0349,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,38.10410959,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 111,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.135,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353799/suppl/GSM2353799_A52084400940728100515421373263889.CEL.gz,0,,NA,GSM2353799
GSM2353800_A52084400940727100515421373263807.CEL,"SUBJ.0349, SLE, week52",GSM2353800,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0349,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,38.10410959,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 111,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.135,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353800/suppl/GSM2353800_A52084400940727100515421373263807.CEL.gz,0,,NA,GSM2353800
GSM2353801_A52084400940118100915421438150769.CEL,"SUBJ.1382, SLE, baseline",GSM2353801,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1382,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,32.52876712,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 144,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.4,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.189,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353801/suppl/GSM2353801_A52084400940118100915421438150769.CEL.gz,0,Reanalyzed by: GSM2351496,NA,GSM2353801
GSM2353802_A52084400940102100915421438150671.CEL,"SUBJ.1382, SLE, week16",GSM2353802,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1382,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,32.52876712,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 144,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.4,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.189,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353802/suppl/GSM2353802_A52084400940102100915421438150671.CEL.gz,0,,NA,GSM2353802
GSM2353803_A52084400940103100915421438150714.CEL,"SUBJ.1382, SLE, week52",GSM2353803,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1382,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,32.52876712,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 144,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.4,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.189,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353803/suppl/GSM2353803_A52084400940103100915421438150714.CEL.gz,0,,NA,GSM2353803
GSM2353804_A52084400939703101515421439062184.CEL,"SUBJ.1300, SLE, baseline",GSM2353804,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1300,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,37.54520548,mex_ca_sa,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.069,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353804/suppl/GSM2353804_A52084400939703101515421439062184.CEL.gz,0,Reanalyzed by: GSM2352511,NA,GSM2353804
GSM2353805_A52084400939410101115421438971343.CEL,"SUBJ.1300, SLE, week16",GSM2353805,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1300,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,37.54520548,mex_ca_sa,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.069,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353805/suppl/GSM2353805_A52084400939410101115421438971343.CEL.gz,0,,NA,GSM2353805
GSM2353806_A52084400939409101115421438971254.CEL,"SUBJ.1300, SLE, week52",GSM2353806,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1300,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,37.54520548,mex_ca_sa,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.069,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353806/suppl/GSM2353806_A52084400939409101115421438971254.CEL.gz,0,,NA,GSM2353806
GSM2353807_A52084400940727100515421373263803.CEL,"SUBJ.1175, SLE, baseline",GSM2353807,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1175,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,amer_ind_ak_native,Female,28.43013699,mex_ca_sa,15,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.733,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353807/suppl/GSM2353807_A52084400940727100515421373263803.CEL.gz,0,Reanalyzed by: GSM2352067,NA,GSM2353807
GSM2353808_A52084400940727100515421373263791.CEL,"SUBJ.1175, SLE, week16",GSM2353808,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1175,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,amer_ind_ak_native,Female,28.43013699,mex_ca_sa,15,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.733,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353808/suppl/GSM2353808_A52084400940727100515421373263791.CEL.gz,0,,NA,GSM2353808
GSM2353809_A52084400940727100515421373263818.CEL,"SUBJ.1175, SLE, week52",GSM2353809,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1175,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,amer_ind_ak_native,Female,28.43013699,mex_ca_sa,15,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.733,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353809/suppl/GSM2353809_A52084400940727100515421373263818.CEL.gz,0,,NA,GSM2353809
GSM2353810_A52084400940102100915421438150685.CEL,"SUBJ.0041, SLE, baseline",GSM2353810,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0041,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,67.22465753,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 31,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.45,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.355,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353810/suppl/GSM2353810_A52084400940102100915421438150685.CEL.gz,0,Reanalyzed by: GSM2351276,NA,GSM2353810
GSM2353811_A52084400940102100915421438150659.CEL,"SUBJ.0041, SLE, week52",GSM2353811,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0041,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,67.22465753,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 31,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.45,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.355,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353811/suppl/GSM2353811_A52084400940102100915421438150659.CEL.gz,0,,NA,GSM2353811
GSM2353812_A52084400939703101515421439062178.CEL,"SUBJ.0698, SLE, baseline",GSM2353812,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0698,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,52.55068493,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.608,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.059,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353812/suppl/GSM2353812_A52084400939703101515421439062178.CEL.gz,0,Reanalyzed by: GSM2351531,NA,GSM2353812
GSM2353813_A52084400939702101515421439062143.CEL,"SUBJ.0698, SLE, week16",GSM2353813,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0698,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,52.55068493,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.608,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.059,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353813/suppl/GSM2353813_A52084400939702101515421439062143.CEL.gz,0,,NA,GSM2353813
GSM2353814_A52084400939412101115421438971507.CEL,"SUBJ.0698, SLE, week52",GSM2353814,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0698,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,52.55068493,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.608,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.059,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353814/suppl/GSM2353814_A52084400939412101115421438971507.CEL.gz,0,,NA,GSM2353814
GSM2353815_A52084400939559101515421438861404.CEL,"SUBJ.0420, SLE, baseline",GSM2353815,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0420,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,43.92328767,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.11,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.151,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353815/suppl/GSM2353815_A52084400939559101515421438861404.CEL.gz,0,Reanalyzed by: GSM2352121,NA,GSM2353815
GSM2353816_A52084400939409101115421438971276.CEL,"SUBJ.0420, SLE, week16",GSM2353816,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0420,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,43.92328767,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.11,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.151,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353816/suppl/GSM2353816_A52084400939409101115421438971276.CEL.gz,0,,NA,GSM2353816
GSM2353817_A52084400939412101115421438971483.CEL,"SUBJ.0420, SLE, week52",GSM2353817,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0420,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,43.92328767,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.11,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.151,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353817/suppl/GSM2353817_A52084400939412101115421438971483.CEL.gz,0,,NA,GSM2353817
GSM2353818_A52084400939558101515421438861325.CEL,"SUBJ.0546, SLE, baseline",GSM2353818,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0546,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,amer_ind_ak_native,Female,50.74043716,mex_ca_sa,26,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.871,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.07,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353818/suppl/GSM2353818_A52084400939558101515421438861325.CEL.gz,0,Reanalyzed by: GSM2352606,NA,GSM2353818
GSM2353819_A52084400939409101115421438971251.CEL,"SUBJ.0546, SLE, week16",GSM2353819,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0546,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,amer_ind_ak_native,Female,50.74043716,mex_ca_sa,26,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.871,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.07,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353819/suppl/GSM2353819_A52084400939409101115421438971251.CEL.gz,0,,NA,GSM2353819
GSM2353820_A52084400939412101115421438971504.CEL,"SUBJ.0546, SLE, week52",GSM2353820,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0546,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,amer_ind_ak_native,Female,50.74043716,mex_ca_sa,26,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.871,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.07,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353820/suppl/GSM2353820_A52084400939412101115421438971504.CEL.gz,0,,NA,GSM2353820
GSM2353821_A52084400939558101515421438861337.CEL,"SUBJ.1674, SLE, baseline",GSM2353821,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1674,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,31.97808219,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.65,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H,c4_at_baseline (g/l): 0.566,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353821/suppl/GSM2353821_A52084400939558101515421438861337.CEL.gz,0,Reanalyzed by: GSM2352626,NA,GSM2353821
GSM2353822_A52084400939497101415421438761047.CEL,"SUBJ.1674, SLE, week16",GSM2353822,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1674,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,31.97808219,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.65,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H,c4_at_baseline (g/l): 0.566,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353822/suppl/GSM2353822_A52084400939497101415421438761047.CEL.gz,0,,NA,GSM2353822
GSM2353823_A52084400939560101515421438861434.CEL,"SUBJ.1674, SLE, week52",GSM2353823,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1674,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,31.97808219,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.65,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H,c4_at_baseline (g/l): 0.566,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353823/suppl/GSM2353823_A52084400939560101515421438861434.CEL.gz,0,,NA,GSM2353823
GSM2353824_A52084400940067100715421373649234.CEL,"SUBJ.0535, SLE, baseline",GSM2353824,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0535,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,52.73497268,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.955,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.156,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353824/suppl/GSM2353824_A52084400940067100715421373649234.CEL.gz,0,Reanalyzed by: GSM2351251,NA,GSM2353824
GSM2353825_A52084400940068100715421373649307.CEL,"SUBJ.0535, SLE, week16",GSM2353825,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0535,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,52.73497268,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.955,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.156,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353825/suppl/GSM2353825_A52084400940068100715421373649307.CEL.gz,0,,NA,GSM2353825
GSM2353826_A52084400940069100715421373649378.CEL,"SUBJ.0535, SLE, week52",GSM2353826,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0535,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,52.73497268,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.955,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.156,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353826/suppl/GSM2353826_A52084400940069100715421373649378.CEL.gz,0,,NA,GSM2353826
GSM2353827_A52084400940102100915421438150687.CEL,"SUBJ.0601, SLE, week16",GSM2353827,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0601,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,55.96986301,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.6,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.274,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353827/suppl/GSM2353827_A52084400940102100915421438150687.CEL.gz,0,,NA,GSM2353827
GSM2353828_A52084400939559101515421438861381.CEL,"SUBJ.0228, SLE, baseline",GSM2353828,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0228,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,53.54794521,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 102,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.094,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353828/suppl/GSM2353828_A52084400939559101515421438861381.CEL.gz,0,Reanalyzed by: GSM2352145,NA,GSM2353828
GSM2353829_A52084400939411101115421438971404.CEL,"SUBJ.0228, SLE, week16",GSM2353829,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0228,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,53.54794521,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 102,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.094,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353829/suppl/GSM2353829_A52084400939411101115421438971404.CEL.gz,0,,NA,GSM2353829
GSM2353830_A52084400939411101115421438971406.CEL,"SUBJ.0228, SLE, week52",GSM2353830,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0228,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,53.54794521,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 102,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.094,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353830/suppl/GSM2353830_A52084400939411101115421438971406.CEL.gz,0,,NA,GSM2353830
GSM2353831_A52084400940726100515421373263746.CEL,"SUBJ.0674, SLE, baseline",GSM2353831,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0674,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,46.6109589,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.818,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.161,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353831/suppl/GSM2353831_A52084400940726100515421373263746.CEL.gz,0,Reanalyzed by: GSM2352271,NA,GSM2353831
GSM2353832_A52084400940729100515421373263950.CEL,"SUBJ.0674, SLE, week16",GSM2353832,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0674,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,46.6109589,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.818,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.161,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353832/suppl/GSM2353832_A52084400940729100515421373263950.CEL.gz,0,,NA,GSM2353832
GSM2353833_A52084400940729100515421373263939.CEL,"SUBJ.0674, SLE, week52",GSM2353833,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0674,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,46.6109589,us_can,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.818,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.161,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353833/suppl/GSM2353833_A52084400940729100515421373263939.CEL.gz,0,,NA,GSM2353833
GSM2353834_A52084400940102100915421438150689.CEL,"SUBJ.0818, SLE, baseline",GSM2353834,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0818,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,63.11506849,us_can,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.899,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.187,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353834/suppl/GSM2353834_A52084400940102100915421438150689.CEL.gz,0,Reanalyzed by: GSM2351063,NA,GSM2353834
GSM2353835_A52084400940119100915421438150832.CEL,"SUBJ.0818, SLE, week16",GSM2353835,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0818,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,63.11506849,us_can,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.899,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.187,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353835/suppl/GSM2353835_A52084400940119100915421438150832.CEL.gz,0,,NA,GSM2353835
GSM2353836_A52084400940103100915421438150728.CEL,"SUBJ.0824, SLE, baseline",GSM2353836,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0824,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,52.84657534,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 141,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.193,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353836/suppl/GSM2353836_A52084400940103100915421438150728.CEL.gz,0,Reanalyzed by: GSM2351353,NA,GSM2353836
GSM2353837_A52084400940102100915421438150683.CEL,"SUBJ.0824, SLE, week16",GSM2353837,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0824,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,52.84657534,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 141,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.193,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353837/suppl/GSM2353837_A52084400940102100915421438150683.CEL.gz,0,,NA,GSM2353837
GSM2353838_A52084400940103100915421438150721.CEL,"SUBJ.0824, SLE, week52",GSM2353838,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0824,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Male,52.84657534,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 141,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.193,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353838/suppl/GSM2353838_A52084400940103100915421438150721.CEL.gz,0,,NA,GSM2353838
GSM2353839_A52084400940102100915421438150692.CEL,"SUBJ.0413, SLE, baseline",GSM2353839,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0413,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,43.24657534,rest_world,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.918,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353839/suppl/GSM2353839_A52084400940102100915421438150692.CEL.gz,0,Reanalyzed by: GSM2352142,NA,GSM2353839
GSM2353840_A52084400940069100715421373649333.CEL,"SUBJ.0413, SLE, week16",GSM2353840,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0413,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,43.24657534,rest_world,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.918,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353840/suppl/GSM2353840_A52084400940069100715421373649333.CEL.gz,0,,NA,GSM2353840
GSM2353841_A52084400940119100915421438150866.CEL,"SUBJ.0413, SLE, week52",GSM2353841,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0413,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,43.24657534,rest_world,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.918,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353841/suppl/GSM2353841_A52084400940119100915421438150866.CEL.gz,0,,NA,GSM2353841
GSM2353842_A52084400939495101415421438760362.CEL,"SUBJ.0892, SLE, baseline",GSM2353842,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0892,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,33.58356164,us_can,21,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 10,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.81,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353842/suppl/GSM2353842_A52084400939495101415421438760362.CEL.gz,0,Reanalyzed by: GSM2352434,NA,GSM2353842
GSM2353843_A52084400940070100715421373649412.CEL,"SUBJ.0892, SLE, week52",GSM2353843,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0892,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,33.58356164,us_can,21,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 10,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.81,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353843/suppl/GSM2353843_A52084400940070100715421373649412.CEL.gz,0,,NA,GSM2353843
GSM2353844_A52084400939410101115421438971299.CEL,"SUBJ.0859, SLE, baseline",GSM2353844,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0859,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,44.87704918,mex_ca_sa,18,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.17,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.245,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353844/suppl/GSM2353844_A52084400939410101115421438971299.CEL.gz,0,Reanalyzed by: GSM2351412,NA,GSM2353844
GSM2353845_A52084400939497101415421438760479.CEL,"SUBJ.0859, SLE, week16",GSM2353845,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0859,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,44.87704918,mex_ca_sa,18,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.17,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.245,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353845/suppl/GSM2353845_A52084400939497101415421438760479.CEL.gz,0,,NA,GSM2353845
GSM2353846_A52084400939412101115421438971482.CEL,"SUBJ.0859, SLE, week52",GSM2353846,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0859,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,44.87704918,mex_ca_sa,18,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.17,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.245,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353846/suppl/GSM2353846_A52084400939412101115421438971482.CEL.gz,0,,NA,GSM2353846
GSM2353847_A52084400940728100515421373263885.CEL,"SUBJ.1760, SLE, baseline",GSM2353847,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1760,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,19.5890411,mex_ca_sa,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.15,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353847/suppl/GSM2353847_A52084400940728100515421373263885.CEL.gz,0,Reanalyzed by: GSM2351961,NA,GSM2353847
GSM2353848_A52084400940728100515421373263888.CEL,"SUBJ.1760, SLE, week16",GSM2353848,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1760,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,19.5890411,mex_ca_sa,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.15,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353848/suppl/GSM2353848_A52084400940728100515421373263888.CEL.gz,0,,NA,GSM2353848
GSM2353849_A52084400940728100515421373263862.CEL,"SUBJ.1760, SLE, week52",GSM2353849,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1760,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,19.5890411,mex_ca_sa,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.15,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353849/suppl/GSM2353849_A52084400940728100515421373263862.CEL.gz,0,,NA,GSM2353849
GSM2353850_A52084400940070100715421373649392.CEL,"SUBJ.0656, SLE, baseline",GSM2353850,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0656,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,28.95081967,rest_world,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 124,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.817,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.159,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353850/suppl/GSM2353850_A52084400940070100715421373649392.CEL.gz,0,Reanalyzed by: GSM2352629,NA,GSM2353850
GSM2353851_A52084400940068100715421373649309.CEL,"SUBJ.0656, SLE, week16",GSM2353851,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0656,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,28.95081967,rest_world,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 124,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.817,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.159,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353851/suppl/GSM2353851_A52084400940068100715421373649309.CEL.gz,0,,NA,GSM2353851
GSM2353852_A52084400940068100715421373649292.CEL,"SUBJ.0656, SLE, week52",GSM2353852,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0656,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,28.95081967,rest_world,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 124,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.817,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.159,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353852/suppl/GSM2353852_A52084400940068100715421373649292.CEL.gz,0,,NA,GSM2353852
GSM2353853_A52084400940729100515421373263947.CEL,"SUBJ.1794, SLE, baseline",GSM2353853,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1794,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,26.24383562,rest_world,15,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 144,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.838,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.133,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353853/suppl/GSM2353853_A52084400940729100515421373263947.CEL.gz,0,Reanalyzed by: GSM2352281,NA,GSM2353853
GSM2353854_A52084400940727100515421373263790.CEL,"SUBJ.1794, SLE, week16",GSM2353854,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1794,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,26.24383562,rest_world,15,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 144,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.838,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.133,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353854/suppl/GSM2353854_A52084400940727100515421373263790.CEL.gz,0,,NA,GSM2353854
GSM2353855_A52084400940729100515421373263942.CEL,"SUBJ.1794, SLE, week52",GSM2353855,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1794,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,26.24383562,rest_world,15,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 144,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.838,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.133,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353855/suppl/GSM2353855_A52084400940729100515421373263942.CEL.gz,0,,NA,GSM2353855
GSM2353856_A52084400940118100915421438150767.CEL,"SUBJ.0062, SLE, baseline",GSM2353856,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0062,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,42.36438356,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.856,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.179,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353856/suppl/GSM2353856_A52084400940118100915421438150767.CEL.gz,0,Reanalyzed by: GSM2351186,NA,GSM2353856
GSM2353857_A52084400940103100915421438150755.CEL,"SUBJ.0062, SLE, week16",GSM2353857,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0062,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,42.36438356,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.856,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.179,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353857/suppl/GSM2353857_A52084400940103100915421438150755.CEL.gz,0,,NA,GSM2353857
GSM2353858_A52084400940103100915421438150719.CEL,"SUBJ.0062, SLE, week52",GSM2353858,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0062,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,42.36438356,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.856,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.179,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353858/suppl/GSM2353858_A52084400940103100915421438150719.CEL.gz,0,,NA,GSM2353858
GSM2353859_A52084400939705101515421439062319.CEL,"SUBJ.0631, SLE, baseline",GSM2353859,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0631,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,21.87704918,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 72,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.961,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.196,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353859/suppl/GSM2353859_A52084400939705101515421439062319.CEL.gz,0,Reanalyzed by: GSM2351390,NA,GSM2353859
GSM2353860_A52084400939705101515421439062296.CEL,"SUBJ.0631, SLE, week16",GSM2353860,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0631,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,21.87704918,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 72,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.961,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.196,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353860/suppl/GSM2353860_A52084400939705101515421439062296.CEL.gz,0,,NA,GSM2353860
GSM2353861_A52084400939702101515421439062136.CEL,"SUBJ.0631, SLE, week52",GSM2353861,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0631,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,21.87704918,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 72,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.961,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.196,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353861/suppl/GSM2353861_A52084400939702101515421439062136.CEL.gz,0,,NA,GSM2353861
GSM2353862_A52084400940728100515421373263859.CEL,"SUBJ.1768, SLE, baseline",GSM2353862,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1768,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,18.73770492,mex_ca_sa,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 127,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.861,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.104,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353862/suppl/GSM2353862_A52084400940728100515421373263859.CEL.gz,0,Reanalyzed by: GSM2352172,NA,GSM2353862
GSM2353863_A52084400940729100515421373263924.CEL,"SUBJ.1768, SLE, week16",GSM2353863,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1768,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,18.73770492,mex_ca_sa,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 127,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.861,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.104,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353863/suppl/GSM2353863_A52084400940729100515421373263924.CEL.gz,0,,NA,GSM2353863
GSM2353864_A52084400940727100515421373263834.CEL,"SUBJ.1768, SLE, week52",GSM2353864,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1768,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,18.73770492,mex_ca_sa,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 127,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.861,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.104,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353864/suppl/GSM2353864_A52084400940727100515421373263834.CEL.gz,0,,NA,GSM2353864
GSM2353865_A52084400939561101515421438861499.CEL,"SUBJ.0300, SLE, baseline",GSM2353865,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0300,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,46.78082192,us_can,18,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.206,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353865/suppl/GSM2353865_A52084400939561101515421438861499.CEL.gz,0,Reanalyzed by: GSM2352075,NA,GSM2353865
GSM2353866_A52084400939411101115421438971413.CEL,"SUBJ.0300, SLE, week16",GSM2353866,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0300,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,46.78082192,us_can,18,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.206,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353866/suppl/GSM2353866_A52084400939411101115421438971413.CEL.gz,0,,NA,GSM2353866
GSM2353867_A52084400939560101515421438861454.CEL,"SUBJ.0300, SLE, week52",GSM2353867,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0300,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,46.78082192,us_can,18,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.206,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353867/suppl/GSM2353867_A52084400939560101515421438861454.CEL.gz,0,,NA,GSM2353867
GSM2353868_A52084400940726100515421373263758.CEL,"SUBJ.0840, SLE, week52",GSM2353868,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0840,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,57.47671233,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.17,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.231,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353868/suppl/GSM2353868_A52084400940726100515421373263758.CEL.gz,0,,NA,GSM2353868
GSM2353869_A52084400940102100915421438150672.CEL,"SUBJ.1566, SLE, baseline",GSM2353869,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1566,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.79508197,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.201,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353869/suppl/GSM2353869_A52084400940102100915421438150672.CEL.gz,0,Reanalyzed by: GSM2351144,NA,GSM2353869
GSM2353870_A52084400940119100915421438150871.CEL,"SUBJ.1566, SLE, week16",GSM2353870,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1566,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.79508197,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.201,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353870/suppl/GSM2353870_A52084400940119100915421438150871.CEL.gz,0,,NA,GSM2353870
GSM2353871_A52084400940103100915421438150710.CEL,"SUBJ.1566, SLE, week52",GSM2353871,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1566,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.79508197,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.201,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353871/suppl/GSM2353871_A52084400940103100915421438150710.CEL.gz,0,,NA,GSM2353871
GSM2353872_A52084400940144101215421438273218.CEL,"SUBJ.0883, SLE, baseline",GSM2353872,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0883,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,26.5260274,europe,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.39,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353872/suppl/GSM2353872_A52084400940144101215421438273218.CEL.gz,0,Reanalyzed by: GSM2351998,NA,GSM2353872
GSM2353873_A52084400940140101215421438273047.CEL,"SUBJ.0883, SLE, week16",GSM2353873,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0883,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,26.5260274,europe,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.39,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353873/suppl/GSM2353873_A52084400940140101215421438273047.CEL.gz,0,,NA,GSM2353873
GSM2353874_A52084400940141101215421438273061.CEL,"SUBJ.0883, SLE, week52",GSM2353874,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0883,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,26.5260274,europe,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.39,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.025,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353874/suppl/GSM2353874_A52084400940141101215421438273061.CEL.gz,0,,NA,GSM2353874
GSM2353875_A52084400939559101515421438861364.CEL,"SUBJ.1649, SLE, baseline",GSM2353875,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1649,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,51.14246575,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.52,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.196,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353875/suppl/GSM2353875_A52084400939559101515421438861364.CEL.gz,0,Reanalyzed by: GSM2352590,NA,GSM2353875
GSM2353876_A52084400939411101115421438971405.CEL,"SUBJ.1649, SLE, week16",GSM2353876,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1649,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,51.14246575,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.52,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.196,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353876/suppl/GSM2353876_A52084400939411101115421438971405.CEL.gz,0,,NA,GSM2353876
GSM2353877_A52084400939411101115421438971389.CEL,"SUBJ.1649, SLE, week52",GSM2353877,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1649,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,51.14246575,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.52,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.196,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353877/suppl/GSM2353877_A52084400939411101115421438971389.CEL.gz,0,,NA,GSM2353877
GSM2353878_A52084400940140101215421438273024.CEL,"SUBJ.0490, SLE, baseline",GSM2353878,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0490,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.7431694,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.8,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.257,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353878/suppl/GSM2353878_A52084400940140101215421438273024.CEL.gz,0,Reanalyzed by: GSM2351567,NA,GSM2353878
GSM2353879_A52084400940140101215421438273009.CEL,"SUBJ.0490, SLE, week16",GSM2353879,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0490,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.7431694,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.8,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.257,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353879/suppl/GSM2353879_A52084400940140101215421438273009.CEL.gz,0,,NA,GSM2353879
GSM2353880_A52084400940103100915421438150725.CEL,"SUBJ.0490, SLE, week52",GSM2353880,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0490,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.7431694,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.8,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.257,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353880/suppl/GSM2353880_A52084400940103100915421438150725.CEL.gz,0,,NA,GSM2353880
GSM2353881_A52084400939409101115421438971263.CEL,"SUBJ.1693, SLE, baseline",GSM2353881,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1693,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,73.53150685,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 141,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.23,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.202,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353881/suppl/GSM2353881_A52084400939409101115421438971263.CEL.gz,0,Reanalyzed by: GSM2352296,NA,GSM2353881
GSM2353882_A52084400939410101115421438971312.CEL,"SUBJ.1693, SLE, week16",GSM2353882,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1693,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,73.53150685,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 141,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.23,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.202,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353882/suppl/GSM2353882_A52084400939410101115421438971312.CEL.gz,0,,NA,GSM2353882
GSM2353883_A52084400939410101115421438971330.CEL,"SUBJ.1693, SLE, week52",GSM2353883,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1693,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,73.53150685,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 141,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.23,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.202,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353883/suppl/GSM2353883_A52084400939410101115421438971330.CEL.gz,0,,NA,GSM2353883
GSM2353884_A52084400939409101115421438971260.CEL,"SUBJ.0938, SLE, baseline",GSM2353884,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0938,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,37.67486339,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.924,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.152,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353884/suppl/GSM2353884_A52084400939409101115421438971260.CEL.gz,0,Reanalyzed by: GSM2352293,NA,GSM2353884
GSM2353885_A52084400939702101515421439062104.CEL,"SUBJ.0938, SLE, week16",GSM2353885,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0938,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,37.67486339,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.924,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.152,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353885/suppl/GSM2353885_A52084400939702101515421439062104.CEL.gz,0,,NA,GSM2353885
GSM2353886_A52084400939702101515421439062106.CEL,"SUBJ.0938, SLE, week52",GSM2353886,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0938,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,37.67486339,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.924,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.152,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353886/suppl/GSM2353886_A52084400939702101515421439062106.CEL.gz,0,,NA,GSM2353886
GSM2353887_A52084400940080100815421437950323.CEL,"SUBJ.1319, SLE, baseline",GSM2353887,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1319,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,30.8715847,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 62,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.758,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.157,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353887/suppl/GSM2353887_A52084400940080100815421437950323.CEL.gz,0,Reanalyzed by: GSM2351599,NA,GSM2353887
GSM2353888_A52084400940080100815421437950348.CEL,"SUBJ.1319, SLE, week16",GSM2353888,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1319,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,30.8715847,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 62,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.758,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.157,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353888/suppl/GSM2353888_A52084400940080100815421437950348.CEL.gz,0,,NA,GSM2353888
GSM2353889_A52084400940083100815421437950541.CEL,"SUBJ.1319, SLE, week52",GSM2353889,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1319,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,30.8715847,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 62,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.758,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.157,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353889/suppl/GSM2353889_A52084400940083100815421437950541.CEL.gz,0,,NA,GSM2353889
GSM2353890_A52084400940118100915421438150770.CEL,"SUBJ.1582, SLE, baseline",GSM2353890,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1582,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,25.76229508,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 147,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.806,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.12,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353890/suppl/GSM2353890_A52084400940118100915421438150770.CEL.gz,0,Reanalyzed by: GSM2351321,NA,GSM2353890
GSM2353891_A52084400940144101215421438273205.CEL,"SUBJ.1582, SLE, week16",GSM2353891,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1582,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,25.76229508,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 147,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.806,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.12,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353891/suppl/GSM2353891_A52084400940144101215421438273205.CEL.gz,0,,NA,GSM2353891
GSM2353892_A52084400940118100915421438150779.CEL,"SUBJ.1582, SLE, week52",GSM2353892,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1582,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,25.76229508,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 147,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.806,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.12,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353892/suppl/GSM2353892_A52084400940118100915421438150779.CEL.gz,0,,NA,GSM2353892
GSM2353893_A52084400940143101215421438273133.CEL,"SUBJ.0217, SLE, baseline",GSM2353893,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0217,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,71.9890411,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 24,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.04,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.16,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353893/suppl/GSM2353893_A52084400940143101215421438273133.CEL.gz,0,Reanalyzed by: GSM2351587,NA,GSM2353893
GSM2353894_A52084400940141101215421438273090.CEL,"SUBJ.0217, SLE, week16",GSM2353894,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0217,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,71.9890411,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 24,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.04,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.16,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353894/suppl/GSM2353894_A52084400940141101215421438273090.CEL.gz,0,,NA,GSM2353894
GSM2353895_A52084400940141101215421438273115.CEL,"SUBJ.0217, SLE, week52",GSM2353895,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0217,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,71.9890411,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 24,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.04,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.16,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353895/suppl/GSM2353895_A52084400940141101215421438273115.CEL.gz,0,,NA,GSM2353895
GSM2353896_A52084400940141101215421438273111.CEL,"SUBJ.0997, SLE, baseline",GSM2353896,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0997,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,41.73224044,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 241,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.584,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.051,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353896/suppl/GSM2353896_A52084400940141101215421438273111.CEL.gz,0,Reanalyzed by: GSM2352413,NA,GSM2353896
GSM2353897_A52084400940143101215421438273167.CEL,"SUBJ.0997, SLE, week16",GSM2353897,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0997,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,41.73224044,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 241,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.584,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.051,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353897/suppl/GSM2353897_A52084400940143101215421438273167.CEL.gz,0,,NA,GSM2353897
GSM2353898_A52084400940141101215421438273088.CEL,"SUBJ.0997, SLE, week52",GSM2353898,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0997,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,41.73224044,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 241,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.584,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.051,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353898/suppl/GSM2353898_A52084400940141101215421438273088.CEL.gz,0,,NA,GSM2353898
GSM2353899_A52084400940728100515421373263871.CEL,"SUBJ.1722, SLE, baseline",GSM2353899,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1722,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,asian,Female,31.83333333,us_can,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 135,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.878,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.222,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353899/suppl/GSM2353899_A52084400940728100515421373263871.CEL.gz,0,Reanalyzed by: GSM2352401,NA,GSM2353899
GSM2353900_A52084400940728100515421373263852.CEL,"SUBJ.1722, SLE, week16",GSM2353900,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1722,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,asian,Female,31.83333333,us_can,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 135,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.878,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.222,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353900/suppl/GSM2353900_A52084400940728100515421373263852.CEL.gz,0,,NA,GSM2353900
GSM2353901_A52084400940729100515421373263938.CEL,"SUBJ.1722, SLE, week52",GSM2353901,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1722,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,asian,Female,31.83333333,us_can,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 135,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.878,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.222,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353901/suppl/GSM2353901_A52084400940729100515421373263938.CEL.gz,0,,NA,GSM2353901
GSM2353902_A52084400940080100815421437950340.CEL,"SUBJ.0172, SLE, baseline",GSM2353902,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0172,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,55.47123288,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 54,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353902/suppl/GSM2353902_A52084400940080100815421437950340.CEL.gz,0,Reanalyzed by: GSM2352327,NA,GSM2353902
GSM2353903_A52084400940081100815421437950400.CEL,"SUBJ.0172, SLE, week16",GSM2353903,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0172,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,55.47123288,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 54,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353903/suppl/GSM2353903_A52084400940081100815421437950400.CEL.gz,0,,NA,GSM2353903
GSM2353904_A52084400940728100515421373263849.CEL,"SUBJ.0172, SLE, week52",GSM2353904,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0172,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,55.47123288,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 54,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353904/suppl/GSM2353904_A52084400940728100515421373263849.CEL.gz,0,,NA,GSM2353904
GSM2353905_A52084400940141101215421438273433.CEL,"SUBJ.0433, SLE, baseline",GSM2353905,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0433,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.32054795,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.39,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.264,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353905/suppl/GSM2353905_A52084400940141101215421438273433.CEL.gz,0,Reanalyzed by: GSM2352675,NA,GSM2353905
GSM2353906_A52084400940143101215421438273168.CEL,"SUBJ.0433, SLE, week16",GSM2353906,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0433,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.32054795,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.39,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.264,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353906/suppl/GSM2353906_A52084400940143101215421438273168.CEL.gz,0,,NA,GSM2353906
GSM2353907_A52084400940141101215421438273073.CEL,"SUBJ.0433, SLE, week52",GSM2353907,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0433,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.32054795,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.39,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.264,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353907/suppl/GSM2353907_A52084400940141101215421438273073.CEL.gz,0,,NA,GSM2353907
GSM2353908_A52084400939472101415421438775722.CEL,"SUBJ.1194, SLE, baseline",GSM2353908,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1194,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,49.4109589,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.162,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353908/suppl/GSM2353908_A52084400939472101415421438775722.CEL.gz,0,Reanalyzed by: GSM2352607,NA,GSM2353908
GSM2353909_A52084400939412101115421438971492.CEL,"SUBJ.1194, SLE, week16",GSM2353909,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1194,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,49.4109589,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.162,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353909/suppl/GSM2353909_A52084400939412101115421438971492.CEL.gz,0,,NA,GSM2353909
GSM2353910_A52084400939495101415421438760351.CEL,"SUBJ.1194, SLE, week52",GSM2353910,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1194,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,49.4109589,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.162,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353910/suppl/GSM2353910_A52084400939495101415421438760351.CEL.gz,0,,NA,GSM2353910
GSM2353911_A52084400940070100715421373649426.CEL,"SUBJ.1323, SLE, baseline",GSM2353911,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1323,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,49.55616438,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 16,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.85,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.069,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353911/suppl/GSM2353911_A52084400940070100715421373649426.CEL.gz,0,Reanalyzed by: GSM2352286,NA,GSM2353911
GSM2353912_A52084400940068100715421373649285.CEL,"SUBJ.1323, SLE, week16",GSM2353912,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1323,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,49.55616438,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 16,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.85,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.069,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353912/suppl/GSM2353912_A52084400940068100715421373649285.CEL.gz,0,,NA,GSM2353912
GSM2353913_A52084400940067100715421373649242.CEL,"SUBJ.1323, SLE, week52",GSM2353913,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1323,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,49.55616438,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 16,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.85,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.069,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353913/suppl/GSM2353913_A52084400940067100715421373649242.CEL.gz,0,,NA,GSM2353913
GSM2353914_A52084400939704101515421439062231.CEL,"SUBJ.1570, SLE, baseline",GSM2353914,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1570,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.48767123,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.845,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.119,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353914/suppl/GSM2353914_A52084400939704101515421439062231.CEL.gz,0,Reanalyzed by: GSM2351690,NA,GSM2353914
GSM2353915_A52084400939702101515421439062108.CEL,"SUBJ.1570, SLE, week16",GSM2353915,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1570,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.48767123,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.845,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.119,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353915/suppl/GSM2353915_A52084400939702101515421439062108.CEL.gz,0,,NA,GSM2353915
GSM2353916_A52084400939560101515421438861431.CEL,"SUBJ.1570, SLE, week52",GSM2353916,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1570,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.48767123,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.845,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.119,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353916/suppl/GSM2353916_A52084400939560101515421438861431.CEL.gz,0,,NA,GSM2353916
GSM2353917_A52084400939705101515421439062282.CEL,"SUBJ.0846, SLE, baseline",GSM2353917,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0846,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,49.71584699,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 19,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.139,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353917/suppl/GSM2353917_A52084400939705101515421439062282.CEL.gz,0,Reanalyzed by: GSM2351534,NA,GSM2353917
GSM2353918_A52084400940118100915421438150783.CEL,"SUBJ.0846, SLE, week16",GSM2353918,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0846,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,49.71584699,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 19,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.139,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353918/suppl/GSM2353918_A52084400940118100915421438150783.CEL.gz,0,,NA,GSM2353918
GSM2353919_A52084400940118100915421438150806.CEL,"SUBJ.0846, SLE, week52",GSM2353919,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0846,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,amer_ind_ak_native,Female,49.71584699,mex_ca_sa,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 19,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.2,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.139,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353919/suppl/GSM2353919_A52084400940118100915421438150806.CEL.gz,0,,NA,GSM2353919
GSM2353920_A52084400939705101515421439062305.CEL,"SUBJ.0576, SLE, week16",GSM2353920,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0576,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,39.97540984,rest_world,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.86,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353920/suppl/GSM2353920_A52084400939705101515421439062305.CEL.gz,0,,NA,GSM2353920
GSM2353921_A52084400939705101515421439062317.CEL,"SUBJ.0576, SLE, week52",GSM2353921,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0576,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,39.97540984,rest_world,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.86,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353921/suppl/GSM2353921_A52084400939705101515421439062317.CEL.gz,0,,NA,GSM2353921
GSM2353922_A52084400939410101115421438971335.CEL,"SUBJ.0951, SLE, baseline",GSM2353922,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0951,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,36.37260274,europe,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.814,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.104,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353922/suppl/GSM2353922_A52084400939410101115421438971335.CEL.gz,0,Reanalyzed by: GSM2351433,NA,GSM2353922
GSM2353923_A52084400939410101115421438971317.CEL,"SUBJ.0951, SLE, week16",GSM2353923,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0951,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,36.37260274,europe,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.814,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.104,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353923/suppl/GSM2353923_A52084400939410101115421438971317.CEL.gz,0,,NA,GSM2353923
GSM2353924_A52084400939409101115421438971258.CEL,"SUBJ.0951, SLE, week52",GSM2353924,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0951,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,36.37260274,europe,14,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.814,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.104,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353924/suppl/GSM2353924_A52084400939409101115421438971258.CEL.gz,0,,NA,GSM2353924
GSM2353925_A52084400940141101215421438273428.CEL,"SUBJ.0289, SLE, baseline",GSM2353925,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0289,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.60821918,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 34,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.118,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353925/suppl/GSM2353925_A52084400940141101215421438273428.CEL.gz,0,Reanalyzed by: GSM2352073,NA,GSM2353925
GSM2353926_A52084400940143101215421438273124.CEL,"SUBJ.0289, SLE, week16",GSM2353926,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0289,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.60821918,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 34,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.118,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353926/suppl/GSM2353926_A52084400940143101215421438273124.CEL.gz,0,,NA,GSM2353926
GSM2353927_A52084400940141101215421438273080.CEL,"SUBJ.0289, SLE, week52",GSM2353927,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0289,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.60821918,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 34,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.118,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353927/suppl/GSM2353927_A52084400940141101215421438273080.CEL.gz,0,,NA,GSM2353927
GSM2353928_A52084400940081100815421437950415.CEL,"SUBJ.0274, SLE, baseline",GSM2353928,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0274,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,59.47123288,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.69,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.26,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353928/suppl/GSM2353928_A52084400940081100815421437950415.CEL.gz,0,Reanalyzed by: GSM2351923,NA,GSM2353928
GSM2353929_A52084400940082100815421437950454.CEL,"SUBJ.0274, SLE, week16",GSM2353929,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0274,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,59.47123288,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.69,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.26,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353929/suppl/GSM2353929_A52084400940082100815421437950454.CEL.gz,0,,NA,GSM2353929
GSM2353930_A52084400940083100815421437950523.CEL,"SUBJ.0274, SLE, week52",GSM2353930,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0274,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,59.47123288,europe,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.69,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.26,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353930/suppl/GSM2353930_A52084400940083100815421437950523.CEL.gz,0,,NA,GSM2353930
GSM2353931_A52084400939412101115421438971517.CEL,"SUBJ.0604, SLE, week16",GSM2353931,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0604,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,35.92896175,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 15,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.964,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.068,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353931/suppl/GSM2353931_A52084400939412101115421438971517.CEL.gz,0,,NA,GSM2353931
GSM2353932_A52084400939412101115421438971505.CEL,"SUBJ.0604, SLE, week52",GSM2353932,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0604,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,35.92896175,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 15,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.964,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.068,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353932/suppl/GSM2353932_A52084400939412101115421438971505.CEL.gz,0,,NA,GSM2353932
GSM2353933_A52084400939561101515421438861527.CEL,"SUBJ.1410, SLE, baseline",GSM2353933,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1410,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,51.03835616,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.261,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353933/suppl/GSM2353933_A52084400939561101515421438861527.CEL.gz,0,Reanalyzed by: GSM2352405,NA,GSM2353933
GSM2353934_A52084400939561101515421438861514.CEL,"SUBJ.1410, SLE, week52",GSM2353934,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1410,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,51.03835616,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.261,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353934/suppl/GSM2353934_A52084400939561101515421438861514.CEL.gz,0,,NA,GSM2353934
GSM2353935_A52084400939495101415421438760321.CEL,"SUBJ.1675, SLE, baseline",GSM2353935,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1675,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,53.34246575,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 30,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.226,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353935/suppl/GSM2353935_A52084400939495101415421438760321.CEL.gz,0,Reanalyzed by: GSM2352534,NA,GSM2353935
GSM2353936_A52084400939472101415421438760294.CEL,"SUBJ.1675, SLE, week52",GSM2353936,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1675,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,53.34246575,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 30,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.68,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.226,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353936/suppl/GSM2353936_A52084400939472101415421438760294.CEL.gz,0,,NA,GSM2353936
GSM2353937_A52084400940102100915421438150693.CEL,"SUBJ.0865, SLE, baseline",GSM2353937,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0865,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,50.35342466,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 147,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.906,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.119,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353937/suppl/GSM2353937_A52084400940102100915421438150693.CEL.gz,0,Reanalyzed by: GSM2352338,NA,GSM2353937
GSM2353938_A52084400940103100915421438150748.CEL,"SUBJ.0865, SLE, week16",GSM2353938,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0865,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,50.35342466,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 147,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.906,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.119,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353938/suppl/GSM2353938_A52084400940103100915421438150748.CEL.gz,0,,NA,GSM2353938
GSM2353939_A52084400940118100915421438150787.CEL,"SUBJ.0865, SLE, week52",GSM2353939,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0865,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,multiple,Female,50.35342466,rest_world,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 147,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.906,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.119,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353939/suppl/GSM2353939_A52084400940118100915421438150787.CEL.gz,0,,NA,GSM2353939
GSM2353940_A52084400939559101515421438861361.CEL,"SUBJ.0325, SLE, baseline",GSM2353940,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0325,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,41.05479452,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.181,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353940/suppl/GSM2353940_A52084400939559101515421438861361.CEL.gz,0,Reanalyzed by: GSM2351948,NA,GSM2353940
GSM2353941_A52084400939409101115421438971239.CEL,"SUBJ.0325, SLE, week16",GSM2353941,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0325,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,41.05479452,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.181,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353941/suppl/GSM2353941_A52084400939409101115421438971239.CEL.gz,0,,NA,GSM2353941
GSM2353942_A52084400939558101515421438861329.CEL,"SUBJ.0325, SLE, week52",GSM2353942,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0325,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,afr_amer,Female,41.05479452,us_can,12,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.32,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.181,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353942/suppl/GSM2353942_A52084400939558101515421438861329.CEL.gz,0,,NA,GSM2353942
GSM2353943_A52084400940067100715421373649229.CEL,"SUBJ.0877, SLE, baseline",GSM2353943,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0877,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,27.81693989,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 11,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.12,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.152,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353943/suppl/GSM2353943_A52084400940067100715421373649229.CEL.gz,0,Reanalyzed by: GSM2351272,NA,GSM2353943
GSM2353944_A52084400940069100715421373649342.CEL,"SUBJ.0877, SLE, week16",GSM2353944,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0877,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,27.81693989,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 11,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.12,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.152,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353944/suppl/GSM2353944_A52084400940069100715421373649342.CEL.gz,0,,NA,GSM2353944
GSM2353945_A52084400940070100715421373649418.CEL,"SUBJ.0877, SLE, week52",GSM2353945,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0877,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,27.81693989,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 11,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.12,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.152,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353945/suppl/GSM2353945_A52084400940070100715421373649418.CEL.gz,0,,NA,GSM2353945
GSM2353946_A52084400940080100815421437950358.CEL,"SUBJ.0829, SLE, baseline",GSM2353946,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0829,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,36.12328767,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 52,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.742,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.088,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353946/suppl/GSM2353946_A52084400940080100815421437950358.CEL.gz,0,Reanalyzed by: GSM2352603,NA,GSM2353946
GSM2353947_A52084400940083100815421437950525.CEL,"SUBJ.0829, SLE, week16",GSM2353947,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0829,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,36.12328767,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 52,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.742,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.088,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353947/suppl/GSM2353947_A52084400940083100815421437950525.CEL.gz,0,,NA,GSM2353947
GSM2353948_A52084400940083100815421437950511.CEL,"SUBJ.0829, SLE, week52",GSM2353948,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0829,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,36.12328767,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 52,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.742,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.088,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353948/suppl/GSM2353948_A52084400940083100815421437950511.CEL.gz,0,,NA,GSM2353948
GSM2353949_A52084400940083100815421437950501.CEL,"SUBJ.1166, SLE, baseline",GSM2353949,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1166,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.1260274,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353949/suppl/GSM2353949_A52084400940083100815421437950501.CEL.gz,0,Reanalyzed by: GSM2351118,NA,GSM2353949
GSM2353950_A52084400940081100815421437950411.CEL,"SUBJ.1166, SLE, week16",GSM2353950,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1166,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.1260274,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353950/suppl/GSM2353950_A52084400940081100815421437950411.CEL.gz,0,,NA,GSM2353950
GSM2353951_A52084400940080100815421437950353.CEL,"SUBJ.1166, SLE, week52",GSM2353951,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1166,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.1260274,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.21,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353951/suppl/GSM2353951_A52084400940080100815421437950353.CEL.gz,0,,NA,GSM2353951
GSM2353952_A52084400940726100515421373263734.CEL,"SUBJ.1405, SLE, baseline",GSM2353952,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1405,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,45.9890411,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 47,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.903,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.159,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353952/suppl/GSM2353952_A52084400940726100515421373263734.CEL.gz,0,Reanalyzed by: GSM2352643,NA,GSM2353952
GSM2353953_A52084400940728100515421373263868.CEL,"SUBJ.1405, SLE, week52",GSM2353953,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1405,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,45.9890411,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 47,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.903,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.159,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353953/suppl/GSM2353953_A52084400940728100515421373263868.CEL.gz,0,,NA,GSM2353953
GSM2353954_A52084400940102100915421438150674.CEL,"SUBJ.0050, SLE, baseline",GSM2353954,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0050,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.77868852,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.803,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.131,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353954/suppl/GSM2353954_A52084400940102100915421438150674.CEL.gz,0,Reanalyzed by: GSM2351101,NA,GSM2353954
GSM2353955_A52084400940102100915421438150655.CEL,"SUBJ.0050, SLE, week16",GSM2353955,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0050,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.77868852,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.803,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.131,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353955/suppl/GSM2353955_A52084400940102100915421438150655.CEL.gz,0,,NA,GSM2353955
GSM2353956_A52084400940103100915421438150716.CEL,"SUBJ.0050, SLE, week52",GSM2353956,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0050,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,41.77868852,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.803,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.131,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353956/suppl/GSM2353956_A52084400940103100915421438150716.CEL.gz,0,,NA,GSM2353956
GSM2353957_A52084400939703101515421439062203.CEL,"SUBJ.0109, SLE, baseline",GSM2353957,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0109,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,46.09315068,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 143,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.964,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353957/suppl/GSM2353957_A52084400939703101515421439062203.CEL.gz,0,Reanalyzed by: GSM2352164,NA,GSM2353957
GSM2353958_A52084400939703101515421439062180.CEL,"SUBJ.0109, SLE, week16",GSM2353958,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.0109,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,46.09315068,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 143,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.964,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353958/suppl/GSM2353958_A52084400939703101515421439062180.CEL.gz,0,,NA,GSM2353958
GSM2353959_A52084400939561101515421438861484.CEL,"SUBJ.0109, SLE, week52",GSM2353959,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.0109,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Male,46.09315068,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 143,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.964,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.186,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353959/suppl/GSM2353959_A52084400939561101515421438861484.CEL.gz,0,,NA,GSM2353959
GSM2353960_A52084400940140101215421438273054.CEL,"SUBJ.0437, SLE, baseline",GSM2353960,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0437,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,55.96986301,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 38,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.721,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353960/suppl/GSM2353960_A52084400940140101215421438273054.CEL.gz,0,Reanalyzed by: GSM2351468,NA,GSM2353960
GSM2353961_A52084400940144101215421438273227.CEL,"SUBJ.0437, SLE, week16",GSM2353961,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0437,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,55.96986301,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 38,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.721,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353961/suppl/GSM2353961_A52084400940144101215421438273227.CEL.gz,0,,NA,GSM2353961
GSM2353962_A52084400939559101515421438861388.CEL,"SUBJ.0437, SLE, week52",GSM2353962,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0437,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,55.96986301,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 38,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.721,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.102,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353962/suppl/GSM2353962_A52084400939559101515421438861388.CEL.gz,0,,NA,GSM2353962
GSM2353963_A52084400939472101415421438760273.CEL,"SUBJ.1670, SLE, baseline",GSM2353963,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1670,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,21.28219178,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 230,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.818,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.098,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353963/suppl/GSM2353963_A52084400939472101415421438760273.CEL.gz,0,Reanalyzed by: GSM2351085,NA,GSM2353963
GSM2353964_A52084400939472101415421438760280.CEL,"SUBJ.1670, SLE, week16",GSM2353964,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1670,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,21.28219178,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 230,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.818,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.098,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353964/suppl/GSM2353964_A52084400939472101415421438760280.CEL.gz,0,,NA,GSM2353964
GSM2353965_A52084400939411101115421438971391.CEL,"SUBJ.1670, SLE, week52",GSM2353965,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1670,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,21.28219178,mex_ca_sa,20,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 230,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.818,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.098,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353965/suppl/GSM2353965_A52084400939411101115421438971391.CEL.gz,0,,NA,GSM2353965
GSM2353966_A52084400940118100915421438150785.CEL,"SUBJ.0369, SLE, baseline",GSM2353966,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0369,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,28.53150685,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 50,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.946,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.194,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353966/suppl/GSM2353966_A52084400940118100915421438150785.CEL.gz,0,Reanalyzed by: GSM2351819,NA,GSM2353966
GSM2353967_A52084400940118100915421438150772.CEL,"SUBJ.0369, SLE, week16",GSM2353967,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0369,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,28.53150685,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 50,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.946,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.194,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353967/suppl/GSM2353967_A52084400940118100915421438150772.CEL.gz,0,,NA,GSM2353967
GSM2353968_A52084400940103100915421438150742.CEL,"SUBJ.0369, SLE, week52",GSM2353968,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0369,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,28.53150685,europe,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 50,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 0.946,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.194,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353968/suppl/GSM2353968_A52084400940103100915421438150742.CEL.gz,0,,NA,GSM2353968
GSM2353969_A52084400939411101115421438971410.CEL,"SUBJ.1653, SLE, baseline",GSM2353969,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1653,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,57.56438356,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.37,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.253,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353969/suppl/GSM2353969_A52084400939411101115421438971410.CEL.gz,0,Reanalyzed by: GSM2351071,NA,GSM2353969
GSM2353970_A52084400939409101115421438971284.CEL,"SUBJ.1653, SLE, week16",GSM2353970,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1653,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,57.56438356,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.37,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.253,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353970/suppl/GSM2353970_A52084400939409101115421438971284.CEL.gz,0,,NA,GSM2353970
GSM2353971_A52084400939495101415421438760344.CEL,"SUBJ.1653, SLE, week52",GSM2353971,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1653,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,57.56438356,rest_world,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.37,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.253,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353971/suppl/GSM2353971_A52084400939495101415421438760344.CEL.gz,0,,NA,GSM2353971
GSM2353972_A52084400940103100915421438150722.CEL,"SUBJ.1534, SLE, baseline",GSM2353972,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1534,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,40.81147541,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.232,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353972/suppl/GSM2353972_A52084400940103100915421438150722.CEL.gz,0,Reanalyzed by: GSM2352016,NA,GSM2353972
GSM2353973_A52084400940119100915421438150860.CEL,"SUBJ.1534, SLE, week16",GSM2353973,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1534,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,40.81147541,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.232,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353973/suppl/GSM2353973_A52084400940119100915421438150860.CEL.gz,0,,NA,GSM2353973
GSM2353974_A52084400940118100915421438150781.CEL,"SUBJ.1534, SLE, week52",GSM2353974,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1534,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,40.81147541,europe,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.07,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.232,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353974/suppl/GSM2353974_A52084400940118100915421438150781.CEL.gz,0,,NA,GSM2353974
GSM2353975_A52084400939472101415421438760260.CEL,"SUBJ.1735, SLE, baseline",GSM2353975,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1735,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,34.51232877,europe,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.894,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353975/suppl/GSM2353975_A52084400939472101415421438760260.CEL.gz,0,Reanalyzed by: GSM2351200,NA,GSM2353975
GSM2353976_A52084400939410101115421438971338.CEL,"SUBJ.1735, SLE, week16",GSM2353976,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1735,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,34.51232877,europe,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.894,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353976/suppl/GSM2353976_A52084400939410101115421438971338.CEL.gz,0,,NA,GSM2353976
GSM2353977_A52084400939410101115421438971345.CEL,"SUBJ.1735, SLE, week52",GSM2353977,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1735,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,34.51232877,europe,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 9,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.894,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.112,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353977/suppl/GSM2353977_A52084400939410101115421438971345.CEL.gz,0,,NA,GSM2353977
GSM2353978_A52084400939409101115421438971250.CEL,"SUBJ.1759, SLE, baseline",GSM2353978,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1759,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,56.95081967,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 43,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.27,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.303,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353978/suppl/GSM2353978_A52084400939409101115421438971250.CEL.gz,0,Reanalyzed by: GSM2351965,NA,GSM2353978
GSM2353979_A52084400939558101515421438861303.CEL,"SUBJ.1759, SLE, week16",GSM2353979,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1759,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,56.95081967,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 43,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.27,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.303,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353979/suppl/GSM2353979_A52084400939558101515421438861303.CEL.gz,0,,NA,GSM2353979
GSM2353980_A52084400939410101115421438971315.CEL,"SUBJ.1759, SLE, week52",GSM2353980,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1759,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,afr_amer,Female,56.95081967,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 43,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.27,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.303,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353980/suppl/GSM2353980_A52084400939410101115421438971315.CEL.gz,0,,NA,GSM2353980
GSM2353981_A52084400940118100915421438150814.CEL,"SUBJ.0215, SLE, baseline",GSM2353981,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0215,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,60.05753425,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.24,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.207,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353981/suppl/GSM2353981_A52084400940118100915421438150814.CEL.gz,0,Reanalyzed by: GSM2352494,NA,GSM2353981
GSM2353982_A52084400940103100915421438150712.CEL,"SUBJ.0215, SLE, week16",GSM2353982,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0215,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,60.05753425,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.24,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.207,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353982/suppl/GSM2353982_A52084400940103100915421438150712.CEL.gz,0,,NA,GSM2353982
GSM2353983_A52084400940119100915421438150877.CEL,"SUBJ.0215, SLE, week52",GSM2353983,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0215,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,afr_amer,Female,60.05753425,us_can,16,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 7,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.24,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.207,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353983/suppl/GSM2353983_A52084400940119100915421438150877.CEL.gz,0,,NA,GSM2353983
GSM2353984_A52084400940728100515421373263870.CEL,"SUBJ.0038, SLE, baseline",GSM2353984,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0038,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,60.96164384,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.08,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.239,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353984/suppl/GSM2353984_A52084400940728100515421373263870.CEL.gz,0,Reanalyzed by: GSM2351213,NA,GSM2353984
GSM2353985_A52084400940728100515421373263894.CEL,"SUBJ.0038, SLE, week16",GSM2353985,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0038,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,60.96164384,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.08,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.239,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353985/suppl/GSM2353985_A52084400940728100515421373263894.CEL.gz,0,,NA,GSM2353985
GSM2353986_A52084400940729100515421373263927.CEL,"SUBJ.0038, SLE, week52",GSM2353986,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0038,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,60.96164384,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.08,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.239,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353986/suppl/GSM2353986_A52084400940729100515421373263927.CEL.gz,0,,NA,GSM2353986
GSM2353987_A52084400939410101115421438971322.CEL,"SUBJ.1100, SLE, baseline",GSM2353987,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1100,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,49.20273973,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 6,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.56,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.28,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353987/suppl/GSM2353987_A52084400939410101115421438971322.CEL.gz,0,Reanalyzed by: GSM2352672,NA,GSM2353987
GSM2353988_A52084400939410101115421438971316.CEL,"SUBJ.1100, SLE, week16",GSM2353988,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1100,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,49.20273973,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 6,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.56,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.28,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353988/suppl/GSM2353988_A52084400939410101115421438971316.CEL.gz,0,,NA,GSM2353988
GSM2353989_A52084400939411101115421438971383.CEL,"SUBJ.1100, SLE, week52",GSM2353989,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1100,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,49.20273973,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 6,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.56,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.28,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353989/suppl/GSM2353989_A52084400939411101115421438971383.CEL.gz,0,,NA,GSM2353989
GSM2353990_A52084400939410101115421438971306.CEL,"SUBJ.1600, SLE, baseline",GSM2353990,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1600,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,48.66939891,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.42,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.326,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353990/suppl/GSM2353990_A52084400939410101115421438971306.CEL.gz,0,Reanalyzed by: GSM2352475,NA,GSM2353990
GSM2353991_A52084400939497101415421438760485.CEL,"SUBJ.1600, SLE, week16",GSM2353991,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1600,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,48.66939891,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.42,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.326,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353991/suppl/GSM2353991_A52084400939497101415421438760485.CEL.gz,0,,NA,GSM2353991
GSM2353992_A52084400939412101115421438971508.CEL,"SUBJ.1600, SLE, week52",GSM2353992,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1600,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,48.66939891,us_can,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 20,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.42,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.326,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353992/suppl/GSM2353992_A52084400939412101115421438971508.CEL.gz,0,,NA,GSM2353992
GSM2353993_A52084400939561101515421438861497.CEL,"SUBJ.1695, SLE, baseline",GSM2353993,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1695,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,47.96986301,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.56,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.272,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353993/suppl/GSM2353993_A52084400939561101515421438861497.CEL.gz,0,Reanalyzed by: GSM2351140,NA,GSM2353993
GSM2353994_A52084400939702101515421439062109.CEL,"SUBJ.1695, SLE, week16",GSM2353994,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1695,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,47.96986301,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.56,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.272,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353994/suppl/GSM2353994_A52084400939702101515421439062109.CEL.gz,0,,NA,GSM2353994
GSM2353995_A52084400939705101515421439062285.CEL,"SUBJ.1695, SLE, week52",GSM2353995,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1695,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,47.96986301,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.56,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.272,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353995/suppl/GSM2353995_A52084400939705101515421439062285.CEL.gz,0,,NA,GSM2353995
GSM2353996_A52084400939496101415421438760396.CEL,"SUBJ.0759, SLE, baseline",GSM2353996,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0759,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,30.02739726,mex_ca_sa,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 122,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.174,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353996/suppl/GSM2353996_A52084400939496101415421438760396.CEL.gz,0,Reanalyzed by: GSM2350963,NA,GSM2353996
GSM2353997_A52084400939409101115421438971283.CEL,"SUBJ.0759, SLE, week16",GSM2353997,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0759,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,30.02739726,mex_ca_sa,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 122,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.174,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353997/suppl/GSM2353997_A52084400939409101115421438971283.CEL.gz,0,,NA,GSM2353997
GSM2353998_A52084400939495101415421438760354.CEL,"SUBJ.0759, SLE, week52",GSM2353998,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0759,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Male,30.02739726,mex_ca_sa,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 122,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.25,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.174,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353998/suppl/GSM2353998_A52084400939495101415421438760354.CEL.gz,0,,NA,GSM2353998
GSM2353999_A52084400940082100815421437950479.CEL,"SUBJ.1242, SLE, baseline",GSM2353999,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1242,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,36.9890411,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.562,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.079,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353999/suppl/GSM2353999_A52084400940082100815421437950479.CEL.gz,0,Reanalyzed by: GSM2351418,NA,GSM2353999
GSM2354000_A52084400940726100515421373263754.CEL,"SUBJ.1242, SLE, week16",GSM2354000,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1242,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,36.9890411,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.562,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.079,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354000/suppl/GSM2354000_A52084400940726100515421373263754.CEL.gz,0,,NA,GSM2354000
GSM2354001_A52084400940081100815421437950381.CEL,"SUBJ.1242, SLE, week52",GSM2354001,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1242,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,36.9890411,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 297,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.562,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.079,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354001/suppl/GSM2354001_A52084400940081100815421437950381.CEL.gz,0,,NA,GSM2354001
GSM2354002_A52084400939472101415421438760298.CEL,"SUBJ.1201, SLE, baseline",GSM2354002,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1201,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,50.76986301,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.47,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.284,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354002/suppl/GSM2354002_A52084400939472101415421438760298.CEL.gz,0,Reanalyzed by: GSM2351487,NA,GSM2354002
GSM2354003_A52084400939472101415421438760258.CEL,"SUBJ.1201, SLE, week52",GSM2354003,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1201,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,50.76986301,us_can,6,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.47,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.284,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354003/suppl/GSM2354003_A52084400939472101415421438760258.CEL.gz,0,,NA,GSM2354003
GSM2354004_A52084400940102100915421438150666.CEL,"SUBJ.1354, SLE, baseline",GSM2354004,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1354,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.55068493,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 109,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.44,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.166,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354004/suppl/GSM2354004_A52084400940102100915421438150666.CEL.gz,0,Reanalyzed by: GSM2352108,NA,GSM2354004
GSM2354005_A52084400940118100915421438150780.CEL,"SUBJ.1354, SLE, week16",GSM2354005,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with Placebo treatment,Homo sapiens,SUBJ.1354,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.55068493,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 109,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.44,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.166,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354005/suppl/GSM2354005_A52084400940118100915421438150780.CEL.gz,0,,NA,GSM2354005
GSM2354006_A52084400940102100915421438150651.CEL,"SUBJ.1354, SLE, week52",GSM2354006,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with Placebo treatment,Homo sapiens,SUBJ.1354,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo,ILLUMINATE-2,white,Female,34.55068493,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 109,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.44,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.166,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354006/suppl/GSM2354006_A52084400940102100915421438150651.CEL.gz,0,,NA,GSM2354006
GSM2354007_A52084400940143101215421438273148.CEL,"SUBJ.0819, SLE, baseline",GSM2354007,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0819,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.60547945,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 85,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.863,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.1,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354007/suppl/GSM2354007_A52084400940143101215421438273148.CEL.gz,0,Reanalyzed by: GSM2352549,NA,GSM2354007
GSM2354008_A52084400940143101215421438273139.CEL,"SUBJ.0819, SLE, week16",GSM2354008,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0819,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.60547945,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 85,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.863,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.1,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354008/suppl/GSM2354008_A52084400940143101215421438273139.CEL.gz,0,,NA,GSM2354008
GSM2354009_A52084400940141101215421438273082.CEL,"SUBJ.0819, SLE, week52",GSM2354009,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.0819,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,40.60547945,europe,10,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 85,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.863,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.1,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354009/suppl/GSM2354009_A52084400940141101215421438273082.CEL.gz,0,,NA,GSM2354009
GSM2354010_A52084400940118100915421438150796.CEL,"SUBJ.1595, SLE, baseline",GSM2354010,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1595,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,35.86612022,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 87,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.52,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.181,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354010/suppl/GSM2354010_A52084400940118100915421438150796.CEL.gz,0,Reanalyzed by: GSM2351252,NA,GSM2354010
GSM2354011_A52084400940103100915421438150737.CEL,"SUBJ.1595, SLE, week16",GSM2354011,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1595,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,35.86612022,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 87,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.52,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.181,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354011/suppl/GSM2354011_A52084400940103100915421438150737.CEL.gz,0,,NA,GSM2354011
GSM2354012_A52084400940144101215421438273220.CEL,"SUBJ.1595, SLE, week52",GSM2354012,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,Homo sapiens,SUBJ.1595,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W,ILLUMINATE-2,white,Female,35.86612022,europe,9,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive,antidsdna_at_baseline (iu): 87,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N,c3_at_baseline (g/l): 1.52,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.181,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354012/suppl/GSM2354012_A52084400940144101215421438273220.CEL.gz,0,,NA,GSM2354012
GSM2354013_A52084400939559101515421438861402.CEL,"SUBJ.0638, SLE, baseline",GSM2354013,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.0638,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.18630137,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.695,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.18,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354013/suppl/GSM2354013_A52084400939559101515421438861402.CEL.gz,0,Reanalyzed by: GSM2351283,NA,GSM2354013
GSM2354014_A52084400939409101115421438971272.CEL,"SUBJ.0638, SLE, week16",GSM2354014,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0638,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.18630137,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.695,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.18,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354014/suppl/GSM2354014_A52084400939409101115421438971272.CEL.gz,0,,NA,GSM2354014
GSM2354015_A52084400939410101115421438971324.CEL,"SUBJ.0638, SLE, week52",GSM2354015,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.0638,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,52.18630137,us_can,8,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.695,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N,c4_at_baseline (g/l): 0.18,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354015/suppl/GSM2354015_A52084400939410101115421438971324.CEL.gz,0,,NA,GSM2354015
GSM2354016_A52084400940080100815421437950325.CEL,"SUBJ.1560, SLE, baseline",GSM2354016,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at baseline,Homo sapiens,SUBJ.1560,baseline,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.7890411,us_can,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.488,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.098,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at baseline,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354016/suppl/GSM2354016_A52084400940080100815421437950325.CEL.gz,0,Reanalyzed by: GSM2352682,NA,GSM2354016
GSM2354017_A52084400940080100815421437950317.CEL,"SUBJ.1560, SLE, week16",GSM2354017,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1560,week16,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.7890411,us_can,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.488,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.098,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354017/suppl/GSM2354017_A52084400940080100815421437950317.CEL.gz,0,,NA,GSM2354017
GSM2354018_A52084400940083100815421437950537.CEL,"SUBJ.1560, SLE, week52",GSM2354018,Public on Oct 25 2016,Oct 18 2016,Oct 25 2016,RNA,1,Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,Homo sapiens,SUBJ.1560,week52,Systemic lupus erythematosus (SLE),treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W,ILLUMINATE-2,white,Female,40.7890411,us_can,11,adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative,antidsdna_at_baseline (iu): 3,c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L,c3_at_baseline (g/l): 0.488,c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L,c4_at_baseline (g/l): 0.098,tissue: Blood,"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction.",total RNA,"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA).",biotin,Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).,9606,The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays,GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.,Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment,"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization.",GPL17586,"Robert,W,Hoffman",hoffman_robert_w@lilly.com,1 317 651 4209,Lilly Bio-Medicines/Immunology,Eli Lilly and Company,Lilly Corporate Center,Indianapolis,IN,46285,USA,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2354nnn/GSM2354018/suppl/GSM2354018_A52084400940083100815421437950537.CEL.gz,0,,NA,GSM2354018